



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁵ : C12N 15/62, 15/12, 15/15 C12N 15/31, C07K 13/00 C12P 21/02, C12N 1/21 A61K 37/64 // (C12N 1/21 C12R 1:19) (A61K 37/64 A61K 37:54)</p>	<p>A1</p>	<p>(11) International Publication Number: WO 92/10575</p> <p>(43) International Publication Date: 25 June 1992 (25.06.92)</p>
<p>(21) International Application Number: PCT/US91/09108</p> <p>(22) International Filing Date: 5 December 1991 (05.12.91)</p> <p>(30) Priority data: 623,611 7 December 1990 (07.12.90) US</p>		<p>(74) Agent: PIERRI, Margaret, A.; Fish & Neave, 875 Third Avenue, New York, NY 10022-6250 (US).</p>
<p>(71) Applicant: BIOGEN, INC. [US/US]; 14 Cambridge Center, Cambridge, MA 02142 (US).</p> <p>(72) Inventors: MARAGANORE, John, M. ; 84 Patrick Road, Tewksbury, MA 01876 (US). CHAO, Betty, H. ; 3 Ridgefield Road, Winchester, MA 01890 (US). STRAUCH, Kathryn, Louise ; 24 Gardner Street, Newton, MA 02158 (US). THOMPSON, Jeffrey, Scott ; 45 Merrimac Street, Woburn, MA 01801 (US).</p>		<p>(81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), MC (European patent), NL (European patent), SE (European patent).</p> <p>Published <i>With international search report.</i></p>

(54) Title: BIFUNCTIONAL INHIBITORS OF THROMBIN AND PLATELET ACTIVATION

```

      B          A          BH          H
      s          sB K          AsgX          1H
      p          pa p          vpih          np
      E          7n n          a1Ao          ca
      1          11 1          1211          21
      \          /          \ //          /
121  AATTCATGAAAGAAGGTACCGTTGCGGTCGTGCTCGAGGTGACGACGTTAACGACTACT
      +-----+-----+-----+-----+-----+-----+-----+-----+-----+
      TTAAGTACTTTCTTCATGGCAAACGGCAGCAGCTCCACTGCTGCAATTGCTGATGA
      PheMetLysGluGlyThrValCysArgArgAlaArgGlyAspAspValAsnAspTyrCys
                                     180

      B          .          H
      s          P          i
      p          s          n
      M          t          d
      1          1          3
181  GCAACGGTATCTCTGCAGGTTGCCCGCGTAACCCGTTCCACTGATGA
      +-----+-----+-----+-----+-----+-----+-----+-----+-----+
      CGTTGCCATAGAGACGTCCAACGGGCGCATGGGCAAGGTGACTACTTCGA
      AsnGlyIleSerAlaGlyCysProArgAsnProPheHisEndEndSer???
                                     232

```

(57) Abstract

The present invention relates to novel, bifunctional inhibitors of both platelet activation and thrombin. These bifunctional inhibitors are characterized by two domains - a glycoprotein IIb/IIIa inhibitory domain and a thrombin inhibitory domain. The invention also relates to DNA sequences which encode the bifunctional inhibitors of this invention, recombinant DNA molecules which contain these DNA sequences and host transformed with these DNA molecules. The invention further relates to the recombinant expression of the bifunctional inhibitors of this invention by transformed hosts as well as to methods for purifying such recombinant bifunctional inhibitors. This invention also provides compositions and methods employing the novel bifunctional inhibitors alone or together with a fibrinolytic agent. Such compositions may be useful in patients for treating thrombotic disease, increasing recanalization time, decreasing reperfusion time, simultaneously inhibiting thrombin- and platelet-mediated functions and inhibiting malignant cell growth.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LJ	Liechtenstein	SU ⁺	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE ⁺	Germany	MC	Monaco	US	United States of America
DK	Denmark				

⁺ Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

- 1 -

BIFUNCTIONAL INHIBITORS OF THROMBIN
AND PLATELET ACTIVATION

TECHNICAL FIELD OF THE INVENTION

5 The present invention relates to novel, bifunctional inhibitors of both platelet activation and thrombin. These bifunctional inhibitors are characterized by two domains -- a glycoprotein IIb/IIIa inhibitory domain and a thrombin inhibitory domain.

10 The invention also relates to DNA sequences which encode the bifunctional inhibitors of this invention, recombinant DNA molecules which contain these DNA sequences and hosts transformed with these DNA molecules. The invention further relates to the

15 recombinant expression of the bifunctional inhibitors of this invention by transformed hosts as well as to methods for purifying such recombinant bifunctional inhibitors. This invention also provides compositions and methods employing the novel bifunctional inhibitors

20 alone or together with a fibrinolytic agent. Such compositions may be useful in patients for treating thrombotic disease, increasing reocclusion time, decreasing reperfusion time, simultaneously inhibiting thrombin- and platelet-mediated functions and

25 inhibiting malignant cell growth.

- 2 -

BACKGROUND ART

Both platelet activation and thrombin-mediated clot formation are essential to hemostasis. However, perturbations in either of these two

5 hemostatic mechanisms may result in the formation of pathogenic thrombi (blood clots) which block blood flow to dependent tissues. This is the case in a variety of life-threatening vascular diseases, such as myocardial infarction, stroke, peripheral arterial occlusion and

10 other blood system thromboses. Since various biochemical pathways contribute to vascular disease, treatment and prevention may focus on either inhibiting platelets, inhibiting thrombin or directly dissolving the blood clot.

15 Therefore, strategies to control platelet aggregation and release are desirable in the treatment of vascular disease [L. A. Harker and M. Gent, "The Use of Agents that Modify Platelet Function in the Management of Thrombotic Disorders" in Hemostasis and

20 Thrombosis, R. W. Colman et al., eds., pp. 1438-56, J. B. Lippincott, Co., Philadelphia, Pennsylvania (1987)]. Furthermore, inhibition of platelet aggregation may also be desirable in the case of extracorporeal treatment of blood, such as in dialysis,

25 cardiopulmonary bypass surgery, storage of platelets in platelet concentrates and following vascular surgery.

Inhibition of platelets is particularly complicated because many different mechanisms may cause activation. These mechanisms involve one of several

30 different receptors on the platelet surface. Recent attention in this area has been directed to glycoprotein IIb/IIIa, the platelet fibrinogen receptor. This platelet surface protein self-associates as a two-chain complex in a calcium-

35 dependent manner, upon stimulation of platelets with

- 3 -

- ADP, epinephrine, thrombin or prostaglandin derivatives and precursors thereof [S. J. Shattil et al., "Changes in the Platelet Membrane Glycoprotein IIb/IIIa Complex During Platelet Activation", J. Biol. Chem., 260, pp. 11107-14 (1985); G. A. Margeurie et al., "Human Platelets Possess an Inducible and Saturable Receptor Specific for Fibrinogen", J. Biol. Chem., 254, pp. 5357-63 (1979)]. This results in platelet aggregation mediated by a cross-linking between
- 10 fibrinogen and the activated glycoprotein IIb/IIIa complexes of two platelets. Glycoprotein IIb/IIIa specifically binds to the Arg-Gly-Asp sequence present in fibrinogen [M. D. Pierschbacher and E. Ruoslahti, "Cell Attachment Activity of Fibronectin Can Be
- 15 Duplicated By Small Synthetic Fragments of the Molecule", Nature, 309, pp. 30-33 (1984); K. M. Yamada and D. W. Kennedy, "Dualistic Nature of Adhesive Protein Function: Fibronectin and Its Biologically Active Peptide Fragments Can Autoinhibit Fibronectin
- 20 Function", J. Cell Biol., 99, pp. 29-36 (1984); N. Ginsberg et al., "Inhibition of Fibronectin Binding to Platelets By Proteolytic Fragments and Synthetic Peptides Which Support Fibroblast Adhesion", J. Biol. Chem., 260, pp. 3931-36 (1985); E. F. Plow et al., "The
- 25 Effect of Arg-Gly-Asp-Containing Peptides on Fibrinogen and Von Willebrand Factor Binding to Platelets", Proc. Nat. Acad. Sci. USA, 82, pp. 8057-61 (1985); T. K. Gartner and J. S. Bennett, "The Tetrapeptide Analogue of the Cell Attachment Site of Fibronectin Inhibits
- 30 Platelet Aggregation and Fibrinogen Binding to Activated Platelets", J. Biol. Chem., 260, pp. 11891-94 (1985); M. Kloczewiak et al., "Localization of a Site Interacting With Human Platelet Receptor on Carboxy-Terminal Segment of Human Fibrinogen Gamma Chain",
- 35 Biochim. Biophys. Res. Comm., 107, pp. 181-87 (1982)].

- 4 -

- Specific inhibitors of glycoprotein IIb/IIIa, such as monoclonal antibodies [J. S. Bennett et al., "Inhibition of Fibrinogen Binding to Stimulated Human Platelets By a Monoclonal Antibody", Proc. Natl. Acad. Sci. USA, 80, pp. 2417-21 (1983); R. P. McEver et al., "Identification of Two Structurally and Functionally Distinct Sites on Human Platelet Membrane Glycoprotein IIb/IIIa Using Monoclonal Antibodies", J. Biol. Chem., 258, pp. 5269-75 (1983); B. S. Coller, "A New Murine Monoclonal Antibody Reports An Activation-Dependent Change in the Conformation and/or Microenvironment of the Platelet Glycoprotein IIb/IIIa Complex", J. Clin. Invest., 76, pp. 107-08 (1985)] and small Arg-Gly-Asp-containing peptides [T. K. Gartner and J. S. Bennett, supra], are less toxic, faster acting and have a shorter duration of effect as compared to aspirin, the most commonly used platelet inhibitor. Further, unlike aspirin, these compounds are effective against a number of different platelet aggregation mechanisms. Both Arg-Gly-Asp-containing peptides and antibodies toward glycoprotein IIb/IIIa demonstrate antithrombotic efficacy in in vivo models of thrombosis [Y. Cadroy et al., "Potent Antithrombotic Effects of Arg-Gly-Asp-Val (RGDV) Peptide In Vivo", Circulat., Part II, 75, p. II-313 (1988); B. S. Coller et al., "Antithrombotic Effect of a Monoclonal Antibody to the Platelet Glycoprotein IIb/IIIa Receptor in an Experimental Animal Model", Blood, 68, pp. 783-86 (1986); S. R. Hanson et al., "Effects of Monoclonal Antibodies Against the Platelet Glycoprotein IIb/IIIa Complex on Thrombosis and Hemostasis in the Baboon", J. Clin. Invest., 81, pp. 149-58 (1988); T. Yasuda et al., "Monoclonal Antibody Against the Platelet Glycoprotein (GP) IIb/IIIa Receptor Prevents Coronary Artery Reocclusion Following Reperfusing With Recombinant

- 5 -

Tissue-type Plasminogen Activator in Dogs", J. Clin. Invest., 81, pp. 1284-91 (1988); B. S. Collier et al., "Inhibition of Human Platelet Function In Vivo With A Monoclonal Antibody", Annals Int. Med., 109, pp. 635-38 (1988)].

In order to effectively inhibit platelet aggregation, Arg-Gly-Asp-containing peptides must be administered at concentrations greater than 10^{-5} M. Such high dosages limit the commercial feasibility of those peptides. Monoclonal antibodies to glycoprotein IIb/IIIa are more potent inhibitors of platelet aggregation, but their synthesis in mouse hybridoma cells poses greater potential immunological complications [S. R. Hanson et al., supra]. In addition, Arg-Gly-Asp peptides and antibodies toward glycoprotein IIb/IIIa fail to block platelet secretion. Therefore, these agents may have a limited effectiveness in vivo due to the proaggregating effects of released platelet elements and their subsequent cascade-like activation of the circulating platelet pool. Finally, monoclonal antibodies toward glycoprotein IIb/IIIa are known to induce thrombocytopenia in both sub-human primates and man [S. R. Hanson et al., supra; H. K. Gold et al., "Pharmacodynamic Study of F(ab')₂ Fragments of Murine Monoclonal Antibody 7E3 Directed Against Human Platelet Glycoprotein IIb/IIIa in Patients with Unstable Angina Pectoris", J. Clin. Invest., 86, pp. 651-59 (1990)].

Recent attempts to obtain more effective antiplatelet agents have centered around snake venoms, some of which contain glycoprotein IIb/IIIa inhibitors. These include the proteins carinatin, also known as "echistatin", purified from Echis carinatus [C. Ouyang et al., "Characterization of the Platelet Aggregation Inducer and Inhibitor from Echis carinatus Snake

- 6 -

Venom", Biochim. Biophys. Acta, 841, pp. 1-7 (1985); European patent application No. 382,538]; trigramin, purified from Trimeresurus gramineus [T. F. Huang et al., "Trigramin", J. Biol. Chem., 262, pp. 16157-63 (1987); European patent application No. 317,053]; a novel homodimeric antiplatelet protein, "applaggin", isolated from the venom of Agkistrodon p. piscivorus [PCT application No. WO 90/08772]; and others [European patent application 382,451]. These glycoprotein

10 IIB/IIIa inhibitors all belong to a family of related snake venom antiplatelet proteins referred to as "disintegrins". Another polypeptide antiplatelet agent, "decorsin", which is structurally related to the disintegrin family, has recently been isolated from the

15 saliva of the leech Macrobdella decora [J. L. Seymour et al., "Decorsin", J. Biol. Chem. 265, pp. 10143-47 (1990)]. It is thus reasonable to conclude that many if not all blood feeding organisms contain an antiplatelet protein related to the disintegrin family.

20 All members of the disintegrin family contain a large number of cysteine residues, several intramolecular disulfide bonds and the sequence Arg-Gly-Asp. The Arg-Gly-Asp sequence in disintegrins is one possible interactive site for IIB/IIIa binding [B.

25 Savage et al., "Binding of the Snake Venom-Derived Proteins Applaggin and Echistatin to the Arginine-Glycine-Aspartic Acid Recognition Site(s) on Platelet Glycoprotein IIB/IIIa Complex Inhibits Receptor Function", J. Biol. Chem., 265, pp. 11766-72 (1990);

30 M. S. Dennis et al., "Platelet Glycoprotein IIB-IIIa Protein Antagonist from Snake Venoms: Evidence for a Family of Platelet-Aggregation Inhibitors", Proc. Natl. Acad. Sci. USA, 87, pp. 2471-75 (1989)], although synthetic mutants of echistatin lacking the Arg residue

35 still exhibit significant, though diminished,

- 7 -

antiplatelet activity. Moreover, a disintegrin from Sistrurus m. barbouri contains a Lys-Gly-Asp for Arg-Gly-Asp substitution and still exhibits effective antiplatelet activity [R. M. Scarborough et al.,

- 5 "Characterization of a Potent and GpIIb-IIIa Specific Platelet Aggregation Inhibitor from the Venom of the Southeastern Pygmy Rattlesnake", Abstract, Circulation, 82, p. III-370 (1990)]. The disintegrins inhibit platelet aggregation by competitively inhibiting
- 10 fibrinogen or von Willebrand factor binding to the glycoprotein IIb/IIIa receptor [Savage et al., supra]. Disintegrins have been found to indirectly inhibit platelet secretion and eicosanoid metabolism as a result of preventing close cell contact of platelets
- 15 [B. H. Chao et al., "Aqkistrodon piscivorus piscivorus Platelet Aggregation Inhibitor: A Potent Inhibitor of Platelet Aggregation", Proc. Natl. Acad. Sci. USA, 86, pp. 8050-54 (1989)].

- Disintegrins have been evaluated as anti-
- 20 thrombotic agents in models of acute platelet-dependent thrombosis and in models of thrombolysis of experimental thrombi [R. J. Shebuski et al., "Characterization and Platelet Inhibitory Activity of Bitstatin, A Potent Arginine-Glycine-Aspartic Acid-
- 25 Containing Peptide from the Venom of the Viper Bitis arietans", J. Biol. Chem., 264, pp. 21550-56 (1989)]. These agents exhibit potent anti-thrombotic effects. However, as with the monoclonal anti-IIb/IIIa antibodies, administration of disintegrins is
- 30 associated with a transient platelet thrombocytopenia in sub-human primates [S. R. Hanson et al., J. Clin. Invest., 81, pp. 149-58 (1988)] and thus, potentially in man.

- Other approaches to the prevention and
- 35 treatment of vascular disease is the antagonism of

- 8 -

thrombin. Thrombin is both a mediator of clot formation and an agonist for platelet activation. Animal studies have shown that inhibition of thrombin alone is a highly effective mechanism for prevention of platelet thrombus formation [S. R. Hanson et al., "Interruption of Acute Platelet-Dependent Thrombosis by the Synthetic Antithrombin D-phenylalanyl-L-propyl-L-arginyll Chloromethyl Ketone", Proc. Natl. Acad. Sci. USA, 85, pp. 3184-88 (1988)]. Heparin, the most widely used thrombin inhibitor in treating vascular disease, does not inhibit thrombin directly. Therefore, it has limited efficacy in inhibiting platelets. This is because heparin activity is neutralized by platelet secretory components, e.g., platelet factor 4 [J. A. Jakubowski and J. M. Maraganore, "Inhibition of Coagulation and Thrombin-Induced Platelet Activities by a Synthetic Dodecapeptide Modeled on the Carboxy-Terminus of Hirudin, Blood, 75, pp. 399-406 (1990)].

An alternative to heparin is the direct thrombin inhibitor, hirudin, which binds to thrombin forming a stoichiometric complex [S. R. Stone et al., "Kinetics of the Inhibition of Thrombin by Hirudin", Biochemistry, 25, pp. 4622-28 (1986)]. Recently, a novel class of hirudin-based peptides has been designed and characterized [J. M. Maraganore et al., "Design and Characterization of Hirulogs: A Novel Class of Bivalent Peptide Inhibitors of Thrombin", Biochemistry, 29, pp. 7095-7101 (1990); United States patent application No. 549,388]. These peptides, called "Hirulogs", are bivalent inhibitors of thrombin, binding to both the catalytic and anion-binding exosite of the enzyme. Hirulogs have been shown to be effective inhibitors of arterial thrombosis in sub-human primates [A. Kelly et al., "Potent Antithrombotic Effects of a Novel Hybrid Antithrombin Peptide In

- 9 -

Vivo", Abstract, Circulation, 82, p. III-603 (1990)] and to improve vessel patency in models of tPA-induced fibrinolysis [P. Klement et al., "Effects of Heparin and Hirulog on tPA-Induced Thrombolysis in a Rat Model", Abstract, Fibrinolysis, 4, p. 9 (1990)]. While hirulogs show promise for the treatment of arterial, platelet-dependent thrombosis, there will be many clinical circumstances where thrombin inhibition alone is insufficient to prevent thrombosis. This is due to the multiplicity of platelet activation agonists, whose importance as mediators of platelet activation may differ depending on the nature of thrombogenesis.

Despite the developments to date, the need still exists for a better inhibitor of platelet activation and thrombus formation. Such an agent should inhibit platelet activation in response to all physiological agonists without causing transient or long-lasting thrombocytopenia. At the same time, such a molecule should inhibit thrombin-mediated fibrin deposition at the site of a clot, thus preventing a clot from growing.

SUMMARY OF THE INVENTION

The present invention provides novel, bifunctional molecules that are capable of inhibiting both platelet activation and thrombin. These bifunctional inhibitors advantageously inhibit platelet-mediated clot formation and growth while simultaneously preventing clot accretion due to fibrin deposition. As will be appreciated from the disclosure to follow, the bifunctional inhibitors of this invention are effective in inhibiting platelet activation associated with vascular disease without causing thrombocytopenia.

- 10 -

The invention also provides compositions comprising these novel bifunctional inhibitors, optionally together with a fibrinolytic agent. These compositions are safe and effective in treating
5 thrombotic disease, for use following vascular or cardiac surgery and for inhibiting metastatic cell growth.

The invention further provides DNA sequences which encode the bifunctional inhibitors disclosed
10 herein as well as vectors comprising those sequences and hosts transformed therewith. The bifunctional inhibitors of this invention may be produced by recombinant DNA techniques, thus allowing for relatively inexpensive production of commercially
15 feasible quantities. Methods for the recombinant production of the bifunctional inhibitors of this invention are provided.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 depicts the nucleotide sequence of a
20 synthetic gene which encodes an antiplatelet polypeptide from the snake Agkistrodon p. piscivorus.

Figure 2 depicts the 14 separate oligonucleotides used to construct the synthetic gene which encodes an antiplatelet polypeptide from the
25 snake Agkistrodon p. piscivorus.

Figure 3 depicts the polylinker region of the vector pNN03.

Figure 4 depicts a restriction map of the vector pNN03.

30 Figure 5 depicts the individual oligonucleotides used to construct the thrombin inhibitory domain portion of the synthetic gene encoding N-appilog.

- 11 -

Figure 6 depicts the individual oligonucleotides used to construct the thrombin inhibitory domain portion of the synthetic gene encoding C-appilog.

5 Figure 7 depicts, in schematic form, the construction of a vector capable of directing the expression of an ompA-C-appilog fusion polypeptide.

 Figure 8 depicts, in schematic form, the construction of a vector capable of directing the
10 expression of an ompA-N-appilog fusion polypeptide.

 Figure 9 depicts, in schematic form, the construction of a vector capable of directing the expression of a malE-appilog fusion polypeptide.

 Figure 10 depicts the DNA and amino acid
15 sequences at the junction between the malE and appilog portions of the malE-appilog fusion protein.

 Figure 11 depicts, in schematic form, an alternate construction of a vector capable of directing expression of a malE-appilog fusion polypeptide.

20 Figure 12 depicts the comparative effects of L-Phe-Hirulog-8, applaggin, a combination of L-Phe-Hirulog-8 and applaggin, and Gly-Ser-Ile-Glu-Gly-Arg-Pro-Glu-Phe-Met-C-appilog on the APTT of normal human plasma.

25 Figure 13 depicts the effect of Gly-Ser-Ile-Glu-Gly-Arg-Pro-Glu-Phe-Met-C-appilog on collagen-induced platelet aggregation.

 Figure 14 depicts the comparative effects of L-Phe-Hirulog-8, applaggin, a combination of L-Phe-Hirulog-8 and applaggin, and Gly-Ser-Ile-Glu-Gly-Arg-Pro-Glu-Phe-Met-C-appilog on thrombin-induced platelet
30 aggregation.

- 12 -

DETAILED DESCRIPTION OF THE INVENTION

The following common abbreviations of the amino acids are used throughout the specification and in the claims:


5	His - histidine	Gly - glycine
	Ala - alanine	Val - valine
	Leu - leucine	Ile - isoleucine
	Pro - proline	Phe - phenylalanine
	Trp - tryptophan	Met - methionine
10	Ser - serine	Thr - threonine
	Cys - cysteine	Tyr - tyrosine
	Asn - asparagine	Gln - glutamine
	Asp - aspartic acid	Glu - glutamic acid
	Lys - lysine	Arg - arginine
15	BOC - <u>tert</u> Butoxycarbonyl	Tyr(OSO ₃ ⁻) - tyrosine-O-sulfate

The term "any amino acid" as used herein includes the L-isomers of the naturally occurring amino acids, as well as other "non-protein" α -amino acids commonly utilized by those in the peptide chemistry arts when preparing synthetic analogs of naturally occurring amino acids. The naturally occurring amino acids are glycine, alanine, valine, leucine, isoleucine, serine, methionine, threonine, phenylalanine, tyrosine, tryptophan, cysteine, proline, histidine, aspartic acid, asparagine, glutamic acid, glutamine, γ -carboxyglutamic acid, arginine, ornithine and lysine. Examples of "non-protein" α -amino acids include norleucine, norvaline, alloisoleucine, homoarginine, thiaproline, dehydroproline, hydroxyproline (Hyp), homoserine, cyclohexylglycine (Chg), α -amino-n-butyric acid (Aba), cyclohexylalanine (Cha), aminophenylbutyric acid (Pba), phenylalanines substituted at the ortho, meta, or para position of the phenyl moiety with one or two of the following: a (C₁-

- 13 -

C₄) alkyl, a (C₁-C₄) alkoxy, halogen or nitro groups or substituted with a methylenedioxy group; β-2- and 3-thienylalanine, β-2- and 3-furanylalanine, β-2-, 3- and 4-pyridylalanine, β-(benzothienyl-2- and 3-yl)alanine, 5 β-(1- and 2-naphthyl)alanine, O-alkylated derivatives of serine, threonine or tyrosine, S-alkylated cysteine, S-alkylated homocysteine, O-sulfate, O-phosphate and O-carboxylate esters of tyrosine, 3- and 5-tyrosine sulfonate, 3- and tyrosine carbonate, 3- and 5-tyrosine 10 phosphonate, O-methylsulfate, O-methylphosphate and O-acetate esters of tyrosine, 3,5-diiodotyrosine, 3-and 5-nitrotyrosine, ε-alkyl lysine, delta-alkyl ornithine, and the D-isomers of the naturally occurring amino acids.

15 The compounds referred to herein as tyrosine sulfate, Tyr(OSO₃⁻) and O-sulfate ester of tyrosine are identical and have the structural formula:



The term "patient" as used in this application refers to any mammal, especially humans.

25 The term "anionic amino acid" as used herein means a meta, para or ortho, mono- or di-substituted phenylalanine, cyclohexylalanine or tyrosine containing a carboxyl, phosphoryl or sulfonyl moiety, as well as S-alkylated cysteine, S-alkylated homocysteine, 30 γ-carboxyglutamic acid, ε-alkyl lysine, delta-alkyl ornithine, glutamic acid, and aspartic acid. Examples of anionic amino acids are phosphothreonine, phosphoserine, phosphotyrosine, tyrosine sulfate, 3- and 5-tyrosine sulfonate, 3- and 5-tyrosine methyl 35 sulfonate, 3-tyrosine methyl phosphonate and the O-methylsulfate ester of tyrosine.





- 14 -

The term "cationic amino acid" as used herein means arginine, lysine or ornithine.

The terms "catalytic site of thrombin", "active site of thrombin" and "active site pocket of thrombin" as used herein, each refer to any or all of the following sites in thrombin: the substrate binding or "S₁" site; the hydrophobic binding or "oily" site; and the site where cleavage of a substrate is actually carried out ("charge relay site").

The term "backbone chain" as used herein, refers to the portion of a chemical structure that defines the smallest number of consecutive bonds that can be traced from one end of that chemical structure to the other. The atomic components that make up a backbone chain may comprise any atoms that are capable of forming bonds with at least two other atoms.

For example, each of the following chemical structures is characterized by a backbone chain of 7 atoms (the atoms which comprise the backbone chain are indicated in boldface):



- 15 -

The term "calculated length" as used in this application, refers to a predicted measurement derived by summing up the bond lengths between the atoms which comprise the backbone chain. Bond lengths between any
5 two given atoms are well known in the art [see, for example, CRC Handbook of Chemistry and Physics, 65th Edition, R. C. Weist, ed., CRC Press, Inc., Boca Raton, FL, pp. F-166-70 (1984)].

The present invention relates to novel,
10 bifunctional molecules capable of inhibiting platelet activation and thrombin-mediated functions. These bifunctional inhibitors are characterized by a glycoprotein IIb/IIIa inhibitory domain and a thrombin inhibitory domain. The thrombin inhibitory domain
15 consists of three parts, ordered in an N-terminal to C-terminal direction relative to any amino acids present in this domain: i) a catalytic site-directed moiety that binds to and inhibits the active site of thrombin; ii) a linker moiety characterized by a
20 backbone chain having a calculated length of between about 18Å and about 42Å; and iii) an anion binding exosite associating moiety.

According to the invention, the bifunctional inhibitor may be structured so that the glycoprotein
25 IIb/IIIa inhibitory domain is at the N-terminus and the thrombin inhibitory domain is at the C-terminus or vice versa.

The glycoprotein IIb/IIIa inhibitory domain of the molecule of this invention is defined as the
30 portion capable of inhibiting the interaction between fibrinogen and its receptor, platelet surface glycoprotein IIb/IIIa. Many inhibitors of glycoprotein IIb/IIIa are known in the art and any of these may be employed in the bifunctional inhibitors of this
35 invention. For example, the glycoprotein IIb/IIIa

- 16 -

inhibitory domain may be a polyclonal or monoclonal antibody to glycoprotein IIb/IIIa, a small Arg-Gly-Asp containing peptide, an Arg-Tyr-Asp containing peptide, any of the known members of the disintegrin family (i.e., snake venom polypeptides such as trigramin, agkistrostatin, bitstatin, echistatin, applaggin), or a polypeptide which mimics the effect of a disintegrin. Preferably, the glycoprotein IIb/IIIa inhibitory domain is a polypeptide having the amino acid sequence:

10 X_1 -Cys- R_1 - R_2 - R_2 - R_3 -Gly-Asp- R_4 - R_2 - R_2 - R_2 -Cys- Y_1 ,
wherein X_1 is hydrogen, at least one amino acid or a bond; Y_1 is OH, at least one amino acid or a bond; R_1 , each R_2 , either the same or different, and R_3 are any amino acid; and R_4 is a bond or any amino acid. The
15 above amino acid sequence is present in all disintegrins sequenced to date [European patent application No. 382,451].

More preferably, R_1 is a cationic amino acid, R_3 is Arg or Lys and R_4 is a dipeptide Tyr-Leu or
20 Tyr(OSO₃⁻)-Leu. When R_3 is Arg or Lys, the glycoprotein IIb/IIIa inhibitory domain contains an Arg-Gly-Asp or a Lys-Gly-Asp sequence -- a sequence present in naturally occurring disintegrins which competitively inhibit the platelet fibrinogen receptor. Most preferably, the
25 glycoprotein IIb/IIIa inhibitory domain of the molecules of this invention comprises the amino acid sequence (SEQ ID NO:1):

30 Glu-Ala-Gly-Glu-Glu-Cys-Asp-Cys-Gly-Ser-Pro-Glu-Asn-Pro-Cys-Asp-Asp-Ala-Ala-Thr-Cys-Lys-Leu-Arg-Pro-Gly-Ala-Gln-Cys-Ala-Glu-Gly-Leu-Cys-Cys-Asp-Gln-Cys-Lys-Phe-Xaa-Lys-Glu-Gly-Thr-Val-Cys-Arg-Arg-Ala-Arg-Gly-Asp-Asp-Val-Asn-Asp-Tyr-Cys-Asn-Gly-Ile-Ser-35 Ala-Gly-Cys-Pro-Arg-Asn-Pro-Phe-His.

When Xaa is Met, the above sequence is the amino acid sequence of "applaggin" (PCT application

72AA

- 17 -


No. WO 90/08772, the disclosure of which is herein incorporated by reference), a glycoprotein IIB/IIIA inhibitor from the snake Agkistrodon p. piscivorus.

It will be understood that if the inhibitors
5 of this invention are produced by recombinant DNA techniques and the glycoprotein IIB/IIIA inhibitory domain is at the N-terminus of the inhibitor, the above sequence may necessarily comprise additional N-terminal amino acids. For example, if the inhibitor is directly
10 expressed by a recombinant host, this domain will contain an N-terminal methionine, required for initiation of translation. If the inhibitor is expressed as a fusion protein, additional N-terminal amino acids attributed to the host polypeptide portion
15 of the fusion protein and/or linkers used to maintain reading frame between the host polypeptide and the glycoprotein IIB/IIIA inhibitory domain may also be present.

The thrombin inhibitory portion of the
20 molecules of this invention consist of three portions, ordered from N- to C-terminus: a catalytic site-directed moiety ("CSDM"), a linker region, and an anion binding exosite associating moiety ("ABEAM").

According to the present invention, the first
25 moiety, CSDM, binds to the active site of thrombin located at or near about Ser-195 and inhibits or retards the amidolytic or estereolytic activity of thrombin.

According to a preferred embodiment, the CSDM
30 has the formula:



wherein X_2 is hydrogen or from 1 to 12 residues, either the same or different, of any amino acid; A_1 is Arg or Lys; and A_2 is a bond or from 1 to 3 residues, either
35 the same or different, of any amino acid. The CSDM

- 18 -

according to this embodiment binds reversibly to the active site of thrombin. In addition, the bond formed between A₁ and Pro is a naturally occurring imide bond, as opposed to an amide bond. The imide bond is cleaved
5 by thrombin at a much slower rate than an amide bond. This accounts for the inhibitory effect of the CSDM.

As stated above, the thrombin inhibitory domain may be located at the N- or C-terminus of the bifunctional inhibitors of this invention. Since the
10 CSDM is always at the N-terminus of the thrombin inhibitory domain, it will either be located at the N-terminus or in the middle of the bifunctional inhibitors of this invention. Most preferably, if the thrombin inhibitory domain is at the N-terminus of the
15 bifunctional inhibitor of this invention, the CSDM consists of the amino acid sequence: Gly-Pro-Arg-Pro (amino acids 11-14 of SEQ ID NO:4), Met-Gly-Pro-Arg-Pro (amino acids 10-14 of SEQ ID NO:4), Ala-Asn-Ser-Gly-Pro-Arg-Pro (amino acids 1-7 of SEQ ID NO:5), Ile-
20 Met-Pro-Arg-Pro (amino acids 1-5 of SEQ ID NO:6), or Gly-Ser-Ile-Glu-Gly-Arg-Pro-Glu-Phe-Met-Gly-Pro-Arg-Pro (amino acids 1-12 of SEQ ID NO:4. If the thrombin inhibitory domain is at the C-terminus of the bifunctional inhibitors of this invention, the CSDM
25 preferably consists of the amino acid sequence: Gly-Gly-Gly-Gly-Gly-Pro-Arg-Pro (amino acids 83-90 of SEQ ID NO:4)

Other CSDMs which may be employed in the bifunctional inhibitors of the present invention are
30 selected from one of three general groups: those described above which bind reversibly to thrombin and are slowly cleaved; those which bind reversibly to thrombin and cannot be cleaved; and those which bind irreversibly to thrombin. Reversible inhibitors bind
35 to the active site of thrombin through non-covalent

- 19 -

interactions, such as ionic bonds, hydrophobic interactions or hydrogen bonding. Irreversible CSDMs form covalent bonds with thrombin.

Examples of non-cleavable, reversible CSDMs are small peptides comprising a derivative of Arg, Lys or ornithine linked by a non-cleavable bond to a backbone chain consisting of from 1 to 9 atoms. The derivative of Arg, Lys or ornithine is characterized by a reduced carboxylate moiety or a carboxylate moiety that is displaced from the α -carbon by a chemical structure characterized by a backbone chain of from 1 to 10 atoms. Examples of such derivatives are β -homoarginine; arginine containing a reduced carboxylate moiety, such as Arg[ψ CH₂NH]; β -homolysine and β -homooronithine.

Other non-cleavable, reversible CSDMs that may be employed in the bifunctional inhibitors of this invention are benzamidine, DAPA, NAPAP and argatroban (argipidine).

Examples of irreversible CSDMs include, but are not limited to, general serine proteinase inhibitors, such as phenylmethylsulfonylfluoride (PMSF), diisopropylfluoro-phosphate (DFP), tosylprolylchloromethylketone (TPCK) and tosyllysylchloromethylketone (TLCK); heterocyclic protease inhibitors, such as isocoumarins; thrombin-specific inhibitors, such as D-Phe-Pro-Arg-CHCl₂ (PPACK); and transition state analogues, such as difluoroketomethylene analogs.


According to the present invention, the second component of the thrombin inhibitory domain of the molecules of this invention is a linker moiety. Because the role of this portion of the bifunctional inhibitor is to provide a bridge between the CSDM and the ABEAM, it is the length of the linker, rather than

- 20 -

its structure, that is of prime importance. The calculated length of the backbone chain which characterizes the linker must be at least about 18Å -- the distance between the catalytic site and the anion binding exosite of thrombin -- and less than about 42Å.

The backbone chain of the linker may comprise any atoms which are capable of bonding to at least two other atoms. Preferably, the backbone chain consists of from 6 to 14 residues, either the same or different, of any amino acid. Most preferably, the linker present in the bifunctional inhibitor of this invention consists of the amino acid sequence: Gly-Gly-Gly-Gly-Asn-Gly-Asp-Phe (amino acids 5-12 of SEQ ID NO:2).

The third portion of the thrombin inhibitory domain of the molecules of this invention is the ABEAM, which binds to the anion binding exosite of thrombin. Preferably, the ABEAM has the formula:



wherein each B_1 , either the same or different, is any anionic amino acid; B_2 is any amino acid; B_3 is Ile, Val, Leu or Phe; B_4 is Tyr, Trp, Phe, Leu, Ile, Val, Pro or a dipeptide consisting of one of these amino acids and any amino acid; and Y_2 is OH or from 1 to 5 residues, either the same or different, of any amino acid.

Peptides which are homologous to the carboxy terminal portion of hirudin have been shown to bind to the anion binding exosite on thrombin [copending United States patent application 314,756 and J. M. Maraganore et al., "Anticoagulant Activity of Synthetic Hirudin Peptides", *J. Biol. Chem.*, 264, pp. 8692-98 (1989); both of which are herein incorporated by reference].

According to a preferred embodiment of this invention, ABEAM is homologous to amino acids 56-64 of hirudin, i.e., each B_1 is Glu, B_2 is Glu, B_3 is Ile and

- 21 -

B₄ is Tyr-Leu or Tyr(OSO₃H)-Leu. In the most preferred embodiment, if the thrombin inhibitory domain is at the N-terminus of the bifunctional inhibitor of this invention, the ABEAM consists of the amino acid sequence: Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gly-Gly-Gly-Gly (amino acids 13-24 of SEQ ID NO:2). If the thrombin inhibitory domain is at the C-terminus of the bifunctional inhibitor the ABEAM consists of the amino acid sequence: Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu (amino acids 89-96 of SEQ ID NO:3).

Other ABEAM components within the scope of this invention may comprise those portions of any molecule known to bind to the anion binding exosite of thrombin. These include amino acids 1675-1686 of Factor V, amino acids 272-285 of platelet glycoprotein Ib, amino acids 415-428 of thrombomodulin, amino acids 245-259 of prothrombin Fragment 2 and amino acids 30 to 44 of fibrinogen A α chain. In addition, the ABEAM component may be selected from any of the hirudin peptide analogues described by J. L. Krstenansky et al., "Development of MDL-28,050, A Small Stable Antithrombin Agent Based On A Functional Domain of the Leech Protein, Hirudin", Thromb. Haemostas., 63, pp. 208-14 (1990) or those described by J. L. Krstenansky et al., "Hirudin and Hirullin C-Terminal Domains: Structural Comparisons and Antithrombin Properties", Abstract, Circulation, 82, p. II-659 (1990).

The structure and synthesis of a wide variety of thrombin inhibitory domains that may be utilized in the bifunctional inhibitors of this invention are described in copending United States application 549,388, the disclosure of which is herein incorporated by reference.

- 22 -

According to a preferred embodiment, the bifunctional inhibitor of this invention is a polypeptide comprising the amino acid sequence (SEQ ID NO:2):

5 Gly-Pro-Arg-Pro-Gly-Gly-Gly-Gly-Asn-Gly-
Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-
Gly-Gly-Gly-Gly-Glu-Ala-Gly-Glu-Glu-Cys-
Asp-Cys-Gly-Ser-Pro-Glu-Asn-Pro-Cys-Asp-
Asp-Ala-Ala-Thr-Cys-Lys-Leu-Arg-Pro-Gly-
10 Ala-Gln-Cys-Ala-Glu-Gly-Leu-Cys-Cys-Asp-
Gln-Cys-Lys-Phe-Xaa-Lys-Glu-Gly-Thr-Val-
Cys-Arg-Arg-Ala-Arg-Gly-Asp-Asp-Val-Asn-
Asp-Tyr-Cys-Asn-Gly-Ile-Ser-Ala-Gly-Cys-
Pro-Arg-Asn-Pro-Phe-His,

15 or a polypeptide comprising the amino acid sequence (SEQ ID NO:3):

Glu-Ala-Gly-Glu-Glu-Cys-Asp-Cys-Gly-Ser-
Pro-Glu-Asn-Pro-Cys-Asp-Asp-Ala-Ala-Thr-
Cys-Lys-Leu-Arg-Pro-Gly-Ala-Gln-Cys-Ala-
20 Glu-Gly-Leu-Cys-Cys-Asp-Gln-Cys-Lys-Phe-
Xaa-Lys-Glu-Gly-Thr-Val-Cys-Arg-Arg-Ala-
Arg-Gly-Asp-Asp-Val-Asn-Asp-Tyr-Cys-Asn-
Gly-Ile-Ser-Ala-Gly-Cys-Pro-Arg-Asn-Pro-
Phe-His-Gly-Gly-Gly-Gly-Gly-Pro-Arg-Pro-
25 Gly-Gly-Gly-Gly-Asn-Gly-Asp-Phe-Glu-Glu-
Ile-Pro-Glu-Glu-Tyr-Leu,

wherein Xaa is any amino acid. The preferred inhibitors of this invention are termed "appilogs". The most preferred bifunctional inhibitors of the present invention consist of SEQ ID NO:4:

Gly-Ser-Ile-Glu-Gly-Arg-Pro-Glu-Phe-Met-
Gly-Pro-Arg-Pro-Gly-Gly-Gly-Gly-Asn-Gly-
Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-
Gly-Gly-Gly-Gly-Glu-Ala-Gly-Glu-Glu-Cys-
35 Asp-Cys-Gly-Ser-Pro-Glu-Asn-Pro-Cys-Asp-
Asp-Ala-Ala-Thr-Cys-Lys-Leu-Arg-Pro-Gly-
Ala-Gln-Cys-Ala-Glu-Gly-Leu-Cys-Cys-Asp-
Gln-Cys-Lys-Phe-Met-Lys-Glu-Gly-Thr-Val-
Cys-Arg-Arg-Ala-Arg-Gly-Asp-Asp-Val-Asn-
40 Asp-Tyr-Cys-Asn-Gly-Ile-Ser-Ala-Gly-Cys-
Pro-Arg-Asn-Pro-Phe-His,

termed "Gly-Ser-Ile-Glu-Gly-Arg-Pro-Glu-Phe-Met-N-appilog"; amino acids 11-106 of SEQ ID NO:4:

- 23 -

5 Gly-Pro-Arg-Pro-Gly-Gly-Gly-Gly-Asn-
 Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-
 Tyr-Leu-Gly-Gly-Gly-Gly-Glu-Ala-Gly-
 Glu-Glu-Cys-Asp-Cys-Gly-Ser-Pro-Glu-
 Asn-Pro-Cys-Asp-Asp-Ala-Ala-Thr-Cys-
 Lys-Leu-Arg-Pro-Gly-Ala-Gln-Cys-Ala-
 Glu-Gly-Leu-Cys-Cys-Asp-Gln-Cys-Lys-
 Phe-Met-Lys-Glu-Gly-Thr-Val-Cys-Arg-
 Arg-Ala-Arg-Gly-Asp-Asp-Val-Asn-Asp-
 10 Tyr-Cys-Asn-Gly-Ile-Ser-Ala-Gly-Cys-
 Pro-Arg-Asn-Pro-Phe-His,

termed "N-appilog"; amino acids 10-106 of SEQ ID NO:4:

15 Met-Gly-Pro-Arg-Pro-Gly-Gly-Gly-Gly-Asn-
 Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-
 Leu-Gly-Gly-Gly-Gly-Glu-Ala-Gly-Glu-Glu-
 Cys-Asp-Cys-Gly-Ser-Pro-Glu-Asn-Pro-Cys-
 Asp-Asp-Ala-Ala-Thr-Cys-Lys-Leu-Arg-Pro-
 Gly-Ala-Gln-Cys-Ala-Glu-Gly-Leu-Cys-Cys-
 Asp-Gln-Cys-Lys-Phe-Met-Lys-Glu-Gly-Thr-
 20 Val-Cys-Arg-Arg-Ala-Arg-Gly-Asp-Asp-Val-
 Asn-Asp-Tyr-Cys-Asn-Gly-Ile-Ser-Ala-Gly-
 Cys-Pro-Arg-Asn-Pro-Phe-His,

termed "Met-N-appilog"; SEQ ID NO:5:

25 Ala-Asn-Ser-Gly-Pro-Arg-Pro-Gly-Gly-Gly-
 Gly-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-
 Glu-Tyr-Leu-Gly-Gly-Gly-Gly-Glu-Ala-Gly-
 Glu-Glu-Cys-Asp-Cys-Gly-Ser-Pro-Glu-Asn-
 Pro-Cys-Asp-Asp-Ala-Ala-Thr-Cys-Lys-Leu-
 Arg-Pro-Gly-Ala-Gln-Cys-Ala-Glu-Gly-Leu-
 30 Cys-Cys-Asp-Gln-Cys-Lys-Phe-Met-Lys-Glu-
 Gly-Thr-Val-Cys-Arg-Arg-Ala-Arg-Gly-Asp-
 Asp-Val-Asn-Asp-Tyr-Cys-Asn-Gly-Ile-Ser-
 Ala-Gly-Cys-Pro-Arg-Asn-Pro-Phe-His,

termed "Ala-Asn-Ser-N-appilog"; SEQ ID NO:6:

35 Ile-Met-Gly-Pro-Arg-Pro-Gly-Gly-Gly-Gly-
 Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-
 Tyr-Leu-Gly-Gly-Gly-Gly-Glu-Ala-Gly-Glu-
 Glu-Cys-Asp-Cys-Gly-Ser-Pro-Glu-Asn-Pro-
 Cys-Asp-Asp-Ala-Ala-Thr-Cys-Lys-Leu-Arg-
 40 Pro-Gly-Ala-Gln-Cys-Ala-Glu-Gly-Leu-Cys-
 Cys-Asp-Gln-Cys-Lys-Phe-Leu-Lys-Glu-Gly-
 Thr-Val-Cys-Arg-Arg-Ala-Arg-Gly-Asp-Asp-
 Val-Asn-Asp-Tyr-Cys-Asn-Gly-Ile-Ser-Ala-
 Gly-Cys-Pro-Arg-Asn-Pro-Phe-His,

45 termed "Ile-Met-N-appilog(Leu₆₅)"; amino acids 3-98 of
 SEQ ID NO:6:

Gly-Pro-Arg-Pro-Gly-Gly-Gly-Gly-Asn-Gly-
 Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-

- 24 -

5 Gly-Gly-Gly-Gly-Glu-Ala-Gly-Glu-Glu-Cys-
Asp-Cys-Gly-Ser-Pro-Glu-Asn-Pro-Cys-Asp-
Asp-Ala-Ala-Thr-Cys-Lys-Leu-Arg-Pro-Gly-
Ala-Gln-Cys-Ala-Glu-Gly-Leu-Cys-Cys-Asp-
Gln-Cys-Lys-Phe-Leu-Lys-Glu-Gly-Thr-Val-
Cys-Arg-Arg-Ala-Arg-Gly-Asp-Asp-Val-Asn-
Asp-Tyr-Cys-Asn-Gly-Ile-Ser-Ala-Gly-Cys-
Pro-Arg-Asn-Pro-Phe-His,

termed "N-appilog(Leu₆₅)"; SEQ ID NO:7:

10 Gly-Ser-Ile-Glu-Gly-Arg-Pro-Glu-Phe-Met-
Glu-Ala-Gly-Glu-Glu-Cys-Asp-Cys-Gly-Ser-
Pro-Glu-Asn-Pro-Cys-Asp-Asp-Ala-Ala-Thr-
Cys-Lys-Leu-Arg-Pro-Gly-Ala-Gln-Cys-Ala-
15 Glu-Gly-Leu-Cys-Cys-Asp-Gln-Cys-Lys-Phe-
Met-Lys-Glu-Gly-Thr-Val-Cys-Arg-Arg-Ala-
Arg-Gly-Asp-Asp-Val-Asn-Asp-Tyr-Cys-Asn-
Gly-Ile-Ser-Ala-Gly-Cys-Pro-Arg-Asn-Pro-
Phe-His-Gly-Gly-Gly-Gly-Gly-Pro-Arg-Pro-
20 Gly-Gly-Gly-Gly-Asn-Gly-Asp-Phe-Glu-Glu-
Ile-Pro-Glu-Glu-Tyr-Leu,

termed "Gly-Ser-Ile-Glu-Gly-Arg-Pro-Glu-Phe-Met-C-
appilog"; amino acids 11-106 of SEQ ID NO:7:

25 Glu-Ala-Gly-Glu-Glu-Cys-Asp-Cys-Gly-Ser-
Pro-Glu-Asn-Pro-Cys-Asp-Asp-Ala-Ala-Thr-
Cys-Lys-Leu-Arg-Pro-Gly-Ala-Gln-Cys-Ala-
Glu-Gly-Leu-Cys-Cys-Asp-Gln-Cys-Lys-Phe-
Met-Lys-Glu-Gly-Thr-Val-Cys-Arg-Arg-Ala-
Arg-Gly-Asp-Asp-Val-Asn-Asp-Tyr-Cys-Asn-
30 Gly-Ile-Ser-Ala-Gly-Cys-Pro-Arg-Asn-Pro-
Phe-His-Gly-Gly-Gly-Gly-Gly-Pro-Arg-Pro-
Gly-Gly-Gly-Gly-Asn-Gly-Asp-Phe-Glu-Glu-
Ile-Pro-Glu-Glu-Tyr-Leu,

termed "C-appilog"; amino acids 10-106 of SEQ ID NO:7:

35 Met-Glu-Ala-Gly-Glu-Glu-Cys-Asp-Cys-Gly-
Ser-Pro-Glu-Asn-Pro-Cys-Asp-Asp-Ala-Ala-
Thr-Cys-Lys-Leu-Arg-Pro-Gly-Ala-Gln-Cys-
Ala-Glu-Gly-Leu-Cys-Cys-Asp-Gln-Cys-Lys-
Phe-Met-Lys-Glu-Gly-Thr-Val-Cys-Arg-Arg-
Ala-Arg-Gly-Asp-Asp-Val-Asn-Asp-Tyr-Cys-
40 Asn-Gly-Ile-Ser-Ala-Gly-Cys-Pro-Arg-Asn-
Pro-Phe-His-Gly-Gly-Gly-Gly-Gly-Pro-Arg-
Pro-Gly-Gly-Gly-Gly-Asn-Gly-Asp-Phe-Glu-
Glu-Ile-Pro-Glu-Glu-Tyr-Leu,

termed "Met-C-appilog"; SEQ ID NO:8:

45 Ala-Asn-Ser-Glu-Ala-Gly-Glu-Glu-Cys-Asp-
Cys-Gly-Ser-Pro-Glu-Asn-Pro-Cys-Asp-Asp-
Ala-Ala-Thr-Cys-Lys-Leu-Arg-Pro-Gly-Ala-
Gln-Cys-Ala-Glu-Gly-Leu-Cys-Cys-Asp-Gln-

- 25 -

5 Cys-Lys-Phe-Met-Lys-Glu-Gly-Thr-Val-Cys-Arg-Arg-Ala-Arg-Gly-Asp-Asp-Val-Asn-Asp-Tyr-Cys-Asn-Gly-Ile-Ser-Ala-Gly-Cys-Pro-Arg-Asn-Pro-Phe-His-Gly-Gly-Gly-Gly-Gly-Pro-Arg-Pro-Gly-Gly-Gly-Gly-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu,

termed "Ala-Asn-Ser-C-appilog"; SEQ ID NO:9:

10 Ile-Met-Glu-Ala-Gly-Glu-Glu-Cys-Asp-Cys-Gly-Ser-Pro-Glu-Asn-Pro-Cys-Asp-Asp-Ala-Ala-Thr-Cys-Lys-Leu-Arg-Pro-Gly-Ala-Gln-Cys-Ala-Glu-Gly-Leu-Cys-Cys-Asp-Gln-Cys-Lys-Phe-Leu-Lys-Glu-Gly-Thr-Val-Cys-Arg-Arg-Ala-Arg-Gly-Asp-Asp-Val-Asn-Asp-Tyr-Cys-Asn-Gly-Ile-Ser-Ala-Gly-Cys-Pro-Arg-15 Asn-Pro-Phe-His-Gly-Gly-Gly-Gly-Gly-Pro-Arg-Pro-Gly-Gly-Gly-Gly-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu,

termed "Ile-Met-C-appilog(Leu₄₁)"; and amino acids 3-98 of SEQ ID NO:9:

20 Glu-Ala-Gly-Glu-Glu-Cys-Asp-Cys-Gly-Ser-Pro-Glu-Asn-Pro-Cys-Asp-Asp-Ala-Ala-Thr-Cys-Lys-Leu-Arg-Pro-Gly-Ala-Gln-Cys-Ala-Glu-Gly-Leu-Cys-Cys-Asp-Gln-Cys-Lys-Phe-Leu-Lys-Glu-Gly-Thr-Val-Cys-Arg-Arg-Ala-25 Arg-Gly-Asp-Asp-Val-Asn-Asp-Tyr-Cys-Asn-Gly-Ile-Ser-Ala-Gly-Cys-Pro-Arg-Asn-Pro-Phe-His-Gly-Gly-Gly-Gly-Gly-Pro-Arg-Pro-Gly-Gly-Gly-Gly-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu,

30 termed "C-appilog(Leu₄₁)".

The designations "N-" and "C-" in the names of these preferred polypeptides refers to the location of the thrombin inhibitory domain relative to the glycoprotein IIb/IIIa inhibitory domain.

35 The bifunctional inhibitors of the present invention may be synthesized by various techniques which are well known in the art. These include isolation of the two separate domains from natural or recombinant sources followed by fusion or cross-40 linking, recombinant DNA techniques, solid-phase peptide synthesis, solution-phase peptide synthesis, organic chemical synthesis techniques, or a combination of these techniques. The choice of technique will, of

- 26 -

course, depend upon the actual composition of the particular bifunctional inhibitor. In a preferred embodiment of this invention, the bifunctional inhibitor is encoded by a synthetic gene and expressed
5 as part of a fusion protein.

The present invention also relates to DNA sequences which encode the preferred inhibitors of this invention. Because these polypeptides are novel and not found in nature, the genes which encode them must
10 by synthesized by chemical means using an oligonucleotide synthesizer. Such oligonucleotides are designed based on the disclosed amino acid sequence of these preferred inhibitors.

Standard methods may be applied to synthesize
15 a gene encoding an appilog. For example, the complete amino acid sequence may be used to construct a back-translated gene. A DNA oligomer containing a nucleotide sequence capable of coding for an appilog may be synthesized in a single step. Alternatively,
20 several smaller oligonucleotides coding for portions of an appilog polypeptide may be synthesized and subsequently ligated together. Preferably, an appilog gene is synthesized as 10-20 separate oligonucleotides which are subsequently linked together. The individual
25 oligonucleotides contain 5' or 3' overhangs for complementary assembly.

A synthetic gene coding for applaggin, an antiplatelet polypeptide from the venom of Agkistrodon p. piscivorus, has previously been described in PCT
30 application No. WO 90/08772. Therefore, the construction of an appilog gene may alternatively be achieved by constructing a DNA sequence encoding the thrombin inhibitory domain and ligating it to the 5' or 3' end of the applaggin gene. The DNA sequence coding
35 for the thrombin inhibitory domain is preferably

- 27 -

synthesized as 3 pairs of partially complementary oligonucleotides containing 5' and/or 3' overhangs for complementary assembly. It will be apparent to those of skill in the art that the pairs of oligonucleotide
 5 will be slightly different depending on whether the final desired construct contains this domain at the N- or C-terminus. This is because the amino acid structure of the thrombin inhibitory domain is different in the two polypeptides.

10 Once assembled, the gene will be characterized by sequences which are recognized by restriction endonucleases, including unique restriction sites for direct assembly into a cloning or an expression vector; preferential codons based upon the
 15 host expression system to be used; and a sequence which, when transcribed, produces a mRNA with minimal secondary structure. Proper assembly may be confirmed by nucleotide sequencing, restriction mapping, and expression of a biologically active polypeptide in a
 20 suitable host.

The DNA sequence according to this invention comprises the nucleic acid sequence (SEQ ID NO:10):

25 GGT CCG CGT CCG GGT GGT GGT GGT AAC GGT GAC
 TTC GAA GAA ATC CCG GAA GAA TAC CTG GGT GGT
 GGT GGT GAA GCT GGT GAA GAA TGC GAC TGC GGA
 TCC CCG GAA AAC CCG TGC GAC GAC GCT GCT ACC
 TGC AAA CTG CGT CCG GGT GCT CAG TGC GCT GAA
 GGT CTG TGC TGC GAC CAG TGC AAA TTC NNN AAA
 GAA GGT ACC GTT TGC CGT CGT GCT CGT GGT GAC
 30 GAC GTT AAC GAC TAC TGC AAC GGT ATC TCT GCA
 GGT TGC CCG CGT AAC CCG TTC CAC,

or (SEQ ID NO:11):

35 GAA GCT GGT GAA GAA TGC GAC TGC GGA TCC CCG
 GAA AAC CCG TGC GAC GAC GCT GCT ACC TGC AAA
 CTG CGT CCG GGT GCT CAG TGC GCT GAA GGT CTG
 TGC TGC GAC CAG TGC AAA TTC NNN AAA GAA GGT
 ACC GTT TGC CGT CGT GCT CGT GGT GAC GAC GTT
 AAC GAC TAC TGC AAC GGT ATC TCT GCA GGT TGC
 CCG CGT AAC CCG TTC CAC GGT GGT GGT GGT GGT
 40 CCG CGT CCG GGT GGT GGT AAC GGT GAC TTC
 GAA GAA ATC CCG GAA GAA TAC CTG,

- 28 -

wherein each N, either the same or different, is any nucleotide. It will be understood by those of skill in the art that, due to the degeneracy of the genetic code, DNA molecules comprising many other nucleotide sequences will also be capable of encoding the preferred inhibitors of this invention. It will also be apparent that many of these DNAs will be faithfully expressed in host transformed with them. Therefore, the present invention relates not only to DNA molecules comprising the nucleotide sequences specifically set forth above, but to all DNA molecules comprising a DNA sequence which encodes the same amino acid sequence and which can be expressed by one or more hosts transformed with them.

The present invention also relates to recombinant DNA molecules comprising the above DNA sequences. Preferably, the recombinant DNA molecules of this invention will be capable of directing expression of the preferred inhibitors of this invention in hosts transformed therewith. As such, the DNA sequence encoding the preferred inhibitors of the invention must be operatively linked to an expression control sequence. The term "operatively linked", as used herein refers to a positioning in a vector so that transcription and translation of the coding sequence is directed by the control sequence.

To construct the recombinant DNA molecules of this invention, the DNA sequences of this invention may be inserted into and expressed using a wide variety of vectors. Furthermore, within each specific expression vector, various sites may be selected for insertion of these DNA sequences. These sites are usually designated by the restriction endonuclease which cuts them. They are well recognized by those of skill in the art. It is, of course, to be understood that an

- 29 -

expression vector useful in this invention need not have a restriction endonuclease site for insertion of the chosen DNA fragment. Instead, the vector may be joined to the fragment by alternative means.

5 The expression vector, and in particular the site chosen therein for insertion of a selected DNA fragment and its operative linking therein to an expression control sequence, is determined by a variety of factors, e.g., number of sites susceptible to a
10 particular restriction enzyme, size of the protein to expressed, susceptibility of the desired protein to proteolytic degradation by host cell enzymes, contamination or binding of the protein to be expressed by host cell proteins difficult to remove during
15 purification, expression characteristics, such as the location of start and stop codons relative to the vector sequences, and other factors recognized by those of skill in the art. The choice of a vector and an insertion site for a DNA sequence is determined by a
20 balance of these factors, not all selections being equally effective for a given case.

Useful expression vectors for eukaryotic hosts include, for example, vectors comprising expression control sequences from SV40, bovine
25 papilloma virus, adenovirus and cytomegalovirus; and vectors useful specifically in insect cells, such as pVL 941. Useful bacterial expression vectors include known bacterial plasmids, e.g., plasmids from E.coli including colE1, pCR1, pBR322, pMB9 and their
30 derivatives; wider host range plasmids, such as RP4; the numerous derivatives of λ phage, e.g., NM 989 and the λ gt series; other DNA phages, e.g., M13 and other Filamentous single-stranded DNA phages; and commercially available high expression vectors, e.g.,
35 the pGEM series and the lambda Zap vectors. Vectors

- 30 -

useful in yeasts include the 2 μ plasmid and derivatives thereof.

Such expression vectors are also characterized by at least one expression control sequence. When the DNA sequences of this invention are inserted in the vector they should be operatively linked to such expression control sequence in order to control and to regulate the expression of that cloned DNA sequence. Examples of useful expression control sequences include the malE system, the OmpA system, the lac system, the trp system, the tac system, the trc system, major operator and promoter regions of phage λ , the control region of fd coat protein, the glycolytic promoters of yeast, e.g., the promoter for 3-phosphoglycerate kinase, the promoters of yeast acid phosphatase, e.g., Pho5, the promoters of the yeast-mating factors, and promoters derived from polyoma, adenovirus, retrovirus, and simian virus, e.g., the early and late promoters of SV40, and other sequences known to control the expression of genes of prokaryotic or eukaryotic cells and their viruses or combinations thereof.

The recombinant DNA molecules of the present invention may also comprise other DNA coding sequences fused to and in frame with the DNA sequences encoding the preferred inhibitors of this invention. For example, a DNA sequence encoding a bacterial or eukaryotic signal sequence may be fused to the 5' end of the appilog DNA sequence. This would allow the expressed product to be either secreted or targeted to a specific subcellular compartment within the host cell. And most signal sequences are removed by the host cell after performing their targeting function, thus obviating the need for their in vitro removal after purification of the desired polypeptide. Many

- 31 -

signal sequences, as well as the DNA sequences encoding them are known in the art. The fusion of such signal sequence DNA to and in frame with the appilog DNA sequences of this invention can be achieved by standard
5 molecular biology techniques.

According to a preferred embodiment, the recombinant DNA molecules of this invention comprise an OmpA signal sequence DNA fused to and in frame with an appilog DNA sequence. When such a fusion protein is
10 expressed in a bacterial host it is secreted into the periplasmic space with concomitant removal of the OmpA signal.

Alternatively, an appilog DNA sequence of this invention may be expressed as a fusion protein by
15 in-frame ligation to a second DNA sequence encoding a host cell polypeptide. The expression of a fusion protein may afford several advantages, such as increased resistance to host cell degradation, ease of identification based upon the activity or antigenicity
20 of the host cell polypeptide portion and ease of purification, based upon the physical or immunological properties of the host cell polypeptide portion.

According to a preferred embodiment, the recombinant DNA molecule of this invention comprises a
25 DNA sequence encoding a protein having the formula:

$$Z_1-Z_2-Z_3-Z_4,$$

wherein Z_1 is hydrogen or the amino acid sequence of the maltose binding protein signal sequence, Z_2 is the amino acid sequence of the maltose binding protein, Z_3
30 is a bond or from 1 to 12 residues, either the same or different, of any amino acid, and Z_4 is the amino acid sequence of N- or C-appilog.

The DNA sequence of the malE gene, which encodes the maltose binding protein and its signal
35 sequence is known in the art [P. Duplay et al.,

- 32 -

J. Biol. Chem., 259, pp. 10606-13 (1984)]. Expression vectors comprising the malE gene have also been previously described [P. D. Riggs, "Expression and Purification of Maltose-Binding Protein Fusions", in 5 Current Protocols in Molecular Biology, F. M. Ausubel et al., eds., John Wiley & Sons, New York, vol. 2, pp. 16.6.1-16.6.12 (1990)]. The advantage of encoding a maltose binding protein-appilog fusion protein is two fold. First, the expressed fusion protein is easily 10 purified by affinity chromatography using an amylose resin which specifically binds maltose binding protein [C.-d. Guan et al., "Vectors That Facilitate the Expression and Purification of Foreign Peptides in Escherichia coli by Fusion to Maltose-Binding Protein", 15 Gene, 67, pp. 21-30 (1988)].

Second, the fusion protein contains a four amino acid Factor Xa cleavage site located at the junction between the maltose binding protein and the appilog, thus allowing easy removal of the maltose 20 binding protein portion from the desired appilog.

According to this embodiment, when Z_1 is the maltose binding protein signal sequence, the fusion protein expressed in a bacterial host is targeted to the periplasm. When Z_1 is hydrogen, the expressed 25 fusion protein will remain in the bacterial host cell cytoplasm.

According to another embodiment of this invention, if amino acid Xaa of the malE-appilog fusion protein is any amino acid except methionine, cyanogen 30 bromide treatment may replace Factor Xa digestion in the process for producing an appilog. As is well known in the art, cyanogen bromide cleaves at the C-terminal side of methionine residues. It will therefore be apparent that such treatment will produce an appilog 35 without any additional N-terminal amino acids (as

- 33 -

opposed to Factor Xa treatment which produces an appilog having from 2 to 10 extra amino terminal amino acids, depending on the construction). According to this embodiment the most preferred appilogs are

- 5 N-appilog(Leu₆₅) (wherein amino acid Xaa, which is residue number 65, is leucine) and C-appilog(Leu₄₁) (wherein amino acid Xaa, which is residue number 41, is leucine).

- The invention also relates to hosts
- 10 transformed with the recombinant DNA molecules described above. Useful hosts which may be transformed with these recombinant DNA molecules and which may be employed to express the bifunctional inhibitors of this invention may include well known eukaryotic and
- 15 prokaryotic hosts, such as strains of E.coli, i.e., E.coli SG-936, E.coli HB 101, E.coli W3110, E.coli X1776, E.coli X2282, E.coli DHI, E.coli DH5-alpha and E.coli MRC1; Pseudomonas; Bacillus, such as Bacillus subtilis; Streptomyces; yeasts and other fungi; animal
- 20 cells, such as COS cells, CHO cells, human cells, insect cells, such as Spodoptera frugiperda (SF9); and plant cells in tissue culture.

- Of course, it will be understood that not all host/expression vector combinations will function with
- 25 equal efficiency in expressing the DNA sequences of this invention or in producing the bifunctional inhibitors of this invention. However, a particular selection of a host-expression vector combination may be made by those of skill in the art, after due
- 30 consideration of the principles set forth herein without departing from the scope of this invention. For example, the selection should be based on a balancing of a number of factors. These include, for example, compatibility of the host and vector, toxicity
- 35 of the proteins encoded by the DNA sequence to the

- 34 -

host, vector copy number and the ability to control that copy number, the expression of other proteins encoded by the vector, such as antibiotic markers, ease of recovery of the desired protein, expression

- 5 characteristics of the DNA sequences and the expression control sequences operatively linked to them, biosafety, costs and the folding, form or any other necessary post-expression modifications of the desired protein.

- 10 The bifunctional inhibitors of the present invention display potent anti-thrombin and anti-platelet activity. These activities may be assayed in vitro using any conventional technique. Preferably, the anti-thrombin assay involves direct determination
15 of the thrombin-inhibitory activity of the molecule. Such techniques measure the inhibition of thrombin-catalyzed cleavage of colorimetric substrates or, more preferably, the increase in thrombin times or increase in activated partial thromboplastin times of human
20 plasma. The latter assay measures factors in the "intrinsic" pathway of coagulation. Alternatively, the assay employed may use purified thrombin and fibrinogen to measure the inhibition of release of fibrinopeptides A or B by radioimmunoassay or ELISA.

- 25 The antiplatelet activity of the molecules of this invention may also be measured by any of a number of conventional platelet assays. Preferably, the assay will measure a change in the degree of aggregation of platelets or a change in the release of a platelet
30 secretory component in the presence of platelet activator. The former may be measured in an aggregometer. The latter may be measured using RIA or ELISA techniques specific for the secreted component.

- The bifunctional inhibitors of the present
35 invention may be formulated into pharmaceutically

- 35 -

acceptable compositions for inhibiting both thrombin- and platelet mediated functions in a patient or in extracorporeal blood. As used in this application, the term "extracorporeal blood" includes blood removed in
5 line from a patient, subjected to extracorporeal treatment, and returned to the patient in processes such as dialysis procedures or blood filtration or blood bypass during surgery. The term also includes blood products which are stored extracorporeally for
10 eventual administration to a patient. Such products include whole blood, platelet concentrates and any other blood fraction in which inhibition of both platelet activation and thrombin is desired."

The bifunctional inhibitors of the present
15 invention are also useful in compositions and methods for the treatment and prophylaxis of various diseases and pathological states attributed to functions and processes mediated by thrombin and/or platelets. These include thrombotic diseases, such as myocardial
20 infarction, stroke, pulmonary embolism, deep vein thrombosis and peripheral arterial occlusion; restenosis following arterial injury or invasive cardiological procedures; acute or chronic atherosclerosis; edema and inflammation; abnormal cell
25 regulatory processes (e.g. secretion, shape changes, proliferation); cancer and metastasis; and neurodegenerative diseases.

According to an alternate embodiment of the present invention, the bifunctional inhibitors may be
30 employed in compositions and methods for decreasing reperfusion or increasing reocclusion time in a patient. These compositions may additionally comprise a pharmaceutically effective amount of a thrombolytic agent.

- 36 -

Thrombolytic agents which may be employed in the compositions of the present invention are those known in the art. Such agents include, but are not limited to, tissue plasminogen activator purified from
5 natural sources, recombinant tissue plasminogen activator, streptokinase, urokinase, prourokinase, anisolated streptokinase plasminogen activator complex (ASPAC), animal salivary gland plasminogen activators and known, biologically active derivatives of any of
10 the above.

In these compositions, the bifunctional inhibitor and the thrombolytic agent work in a complementary fashion to dissolve blood clots, resulting in decreased reperfusion times and increased
15 reocclusion times in patients treated with them. Specifically, the thrombolytic agent dissolves the clot, while the bifunctional inhibitor prevents newly exposed, clot-entrapped or clot-bound thrombin, as well as platelets present at the clot site, from
20 regenerating the clot. The use of the bifunctional inhibitor in the compositions of this invention advantageously allows the administration of a thrombolytic reagent in dosages previously considered too low to result in thrombolytic effects if given
25 alone. This avoids some of the undesirable side effects associated with the use of thrombolytic agents, such as bleeding complications.

The dosage and dose rate of the bifunctional inhibitor of this invention will depend on a variety of
30 factors, such as the size of the patient, the specific pharmaceutical composition used, the object of the treatment, i.e., therapy or prophylaxis, the nature of the thrombotic disease to be treated, and the judgment of the treating physician. A pharmaceutically
35 effective amount of a bifunctional inhibitor of this

- 37 -

invention will normally be in the dosage range of between about 0.001 - 500 mg/kg body weight, preferably about 0.1 - 50 mg/kg body weight. For the treatment of extracorporeal blood, the bifunctional inhibitors of the present invention should be used at about 0.005 - 50 µg/ml, preferably at about 0.5 - 5 µg/ml of extracorporeal blood. It should be understood that other dosages outside of these illustrative ranges may be employed in the pharmaceutical compositions of this invention.

In compositions containing a thrombolytic agent, a pharmaceutically effective dose of the thrombolytic is between about 10% and 80% of the conventional dosage range. The "conventional dosage range" of a thrombolytic agent is the daily dosage used when that agent is employed in a monotherapy. [Physician's Desk Reference 1989, 43rd Edition, Edward R. Barnhart, publisher]. That conventional dosage range will, of course, vary depending on the thrombolytic agent employed. Examples of conventional dosage ranges are as follows: urokinase - 500,000 to 6,250,000 units/patient; streptokinase - 140,000 to 2,500,000 units/patient; tPA - 0.5 to 5.0 mg/kg body weight; ASPAC - 0.1 to 10 units/kg body weight.

Once improvement in the patient's condition has occurred, a maintenance dose of a composition of this invention is administered, if necessary. Subsequently, the dosage or the frequency of administration, or both, may be reduced, as a function of the symptoms, to a level at which the improved condition is retained. When the symptoms have been alleviated to the desired level, treatment should cease. Patients may, however, require intermittent treatment upon any recurrence of disease symptoms.

- 38 -

The pharmaceutically acceptable compositions of the present invention preferably include at least one pharmaceutically acceptable carrier. In addition, the pharmaceutically acceptable compositions of the present invention also comprise a pharmaceutically acceptable buffer, preferably phosphate buffered saline, together with a pharmaceutically acceptable compound for adjusting isotonic pressure, such as sodium chloride, mannitol or sorbitol.

Various dosage forms may be employed to administer the compositions and combinations of this invention. These include, but are not limited to, parenteral administration, oral administration and topical application. The compositions and combinations of this invention may be administered to the patient in any pharmaceutically acceptable dosage form, including those which may be administered to a patient intravenously as bolus or by continued infusion, intramuscularly -- including paravertebrally and periarticularly -- subcutaneously, intracutaneously, intra-articularly, intrasynovially, intrathecally, intra-lesionally, periostally or by oral, nasal, or topical routes. Such compositions and combinations are preferably adapted for topical, nasal, oral and parenteral administration, but, most preferably, are formulated for parenteral administration.

Parenteral compositions are most preferably administered intravenously either in a bolus form or as a constant infusion. If the thrombin inhibitor is being used as an antiplatelet compound, constant infusion is preferred. If the thrombin inhibitor is being used as an anticoagulant, a subcutaneous or intravenous bolus injection is preferred. For parenteral administration, fluid unit dose forms are prepared which contain a thrombin inhibitor of the

- 39 -

present invention and a sterile vehicle. The thrombin inhibitor may be either suspended or dissolved, depending on the nature of the vehicle and the nature of the particular thrombin inhibitor. Parenteral compositions are normally prepared by dissolving the thrombin inhibitor in a vehicle, optionally together with other components, and filter sterilizing before filling into a suitable vial or ampule and sealing. Preferably, adjuvants such as a local anesthetic, preservatives and buffering agents are also dissolved in the vehicle. The composition may then be frozen and lyophilized to enhance stability.

Parenteral suspensions are prepared in substantially the same manner, except that the active component is suspended rather than dissolved in the vehicle. Sterilization of the compositions is preferably achieved by exposure to ethylene oxide before suspension in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of its components.

Tablets and capsules for oral administration may contain conventional excipients, such as binding agents, fillers, diluents, tableting agents, lubricants, disintegrants, and wetting agents. The tablet may be coated according to methods well known in the art. Suitable fillers which may be employed include cellulose, mannitol, lactose and other similar agents. Suitable disintegrants include, but are not limited to, starch, polyvinylpyrrolidone and starch derivatives, such as sodium starch glycolate. Suitable lubricants include, for example, magnesium stearate. Suitable wetting agents include sodium lauryl sulfate.

Oral liquid preparations may be in the form of aqueous or oily suspensions, solutions, emulsions,

- 40 -

syrups or elixirs, or may be presented as a dry product for reconstitution with water or another suitable vehicle before use. Such liquid preparations may contain conventional additives. These include

5 suspending agents; such as sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminum stearate gel or hydrogenated edible fats; emulsifying agents which include lecithin, sorbitan monooleate, polyethylene

10 glycols, or acacia; non-aqueous vehicles, such as almond oil, fractionated coconut oil, and oily esters; and preservatives, such as methyl or propyl p-hydroxybenzoate or sorbic acid.

Compositions formulated for topical

15 administration may, for example, be in aqueous jelly, oily suspension or emulsified ointment form.

This invention also relates to methods employing the bifunctional inhibitors of this invention in the treatment of tumor metastases. The treatment of

20 tumor metastases is manifested by the inhibition of different facets of metastatic cell growth by the two different inhibitory domains of the bifunctional inhibitor. The thrombin inhibitory domain counteracts a procoagulant enzyme present in many cancer cells.

25 This enzyme activates the conversion of Factor X to Factor Xa in the coagulation cascade, resulting in fibrin deposition which, in turn, serves as a substrate for tumor growth. By inhibiting thrombin, fibrin deposition is decreased, thus decreasing the sites upon

30 which tumor cells may grow.

The glycoprotein IIb/IIIa inhibitory domain inhibits the binding of tumor cells to cell matrix proteins. It has previously been shown that Arg-Gly-Asp-containing peptides and polypeptides inhibit the

35 binding of tumor cells to fibronectin and vitronectin

- 41 -

[M. J. Humphries et al., "Investigation of the Biological Effects of Anti-Cell Adhesive Synthetic Peptides that Inhibit Experimental Metastasis of B16-F10 Murine Myeloma Cells", J. Clin. Invest., 81, p. 782 (1988)]. And trigramin has been shown to inhibit the adhesion of human melanoma cells to a fibronectin matrix [K. A. Knudsen et al., "Trigramin, An RGD-Containing Peptide from Snake Venom, Inhibits Cell-Substratum Adhesion of Human Melanoma Cells", Exp. Cell. Res., 179, pp. 42-49 (1988)]. As described herein, the preferred glycoprotein IIb/IIIa domain comprises an Arg-Gly-Asp sequence. Therefore, it will inhibit cancer cell binding to extracellular matrix. It can be readily seen that the bifunctional inhibitors of this invention may serve to interrupt both metastatic cell-mediated deposition of fibrin and the binding of metastatic cells to extracellular matrix. Each of these inhibitory functions can decrease metastatic cell growth. Accordingly, the molecules of this invention may be employed in the treatment of cancer.

In order that this invention may be more fully understood, the following examples are set forth. It should be understood that these examples are for illustrative purposes only and are not to be construed as limiting this invention in any manner.

Unless otherwise indicated, all restriction digests described in the following examples were performed for 2 hours at 37°C using restriction enzymes obtained from New England Biolabs (Beverly, MA) in the manufacturer's recommended buffer. All other standard molecular biology procedures, such as kinasing, ligation, transfections, plasmid preparation, DNA extractions, ethanol precipitations, agarose gel electrophoresis, electroelution, etc. were performed as

- 42 -

described in T. Maniatis et al., Molecular Cloning - A Laboratory Manual, Cold Spring Harbor Laboratory (1982).

EXAMPLE 1

5 Synthesis Of Appilog Genes

A synthetic gene encoding applaggin, an antiplatelet polypeptide from the snake Agkistrodon p. piscivorus has previously been described in WO 90/08772. The gene was designed using the complete
10 amino acid sequence of the natural protein (SEQ ID NO:1) and a back-translation computer program (University of Wisconsin, Genetic Computer Group, Sequence Analysis Software Package, Version 5.2). The total gene, 229 base pairs, was synthesized as 14
15 different oligomers which, when ligated together, form the restriction sequences shown in Figure 1. As illustrated in Figure 2, the 14 oligomers were synthesized as 7 essentially complementary pairs of oligonucleotides. The protruding sequences at joining
20 sites of complementary pairs of oligomers were 6 bases in length. The 14 oligomers were assembled in the cloning vector pNN03, a derivative of the commercially available plasmid pUC8. It was created by cleaving out the entire polylinker region of pUC8 by digestion with
25 HindIII and EcoRI. An alternate polylinker containing different restriction sites (Figure 3) was synthesized by standard procedures and ligated in the HindIII/EcoRI-cleaved pUC8. A restriction map of pNN03 is depicted in Figure 4.

30 Plasmid pNN03 was cleaved with restriction enzymes NcoI and HindIII. The 14 oligomers were added to the cleaved vector and ligation was achieved with T4 ligase. E.coli cells were then transfected with the ligated mixture and colonies expressing tetracycline

- 43 -

resistance were isolated. Plasmids were isolated from these colonies and examined by restriction mapping and nucleotide sequencing to determine if they contain the intact synthetic applaggin gene. One of the plasmids demonstrating the integrity of an assembled vector, termed pNN03-applaggin, was used to construct the appilog genes of this invention.

To construct the Met-N-appilog gene, we digested 21.6 ng of pNN03-applaggin with 50 units of BsmI at 60°C for 2 hours. We then adjusted the NaCl concentration up to 150 mM, added 50 units of NcoI and continued digestion at 37°C for an additional 2 hours. The digestion mixture was electrophoresed on a 0.7% agarose gel run at 100 volts for approximately 1 hour and visualized with ethidium bromide. We excised the large fragment from the gel and electroeluted the DNA. Electroelution was performed at 100 volts for 1 hour.

We synthesized the portion of the gene coding for the thrombin inhibitory domain of Met-N-appilog as 3 pairs of complementary oligonucleotides containing 5' and 3' overhangs for complementary assembly (Figure 5). Additionally, oligonucleotide 1 contained an overhang that complemented the NcoI end of the fragment from pNN03-applaggin (CATG), while oligonucleotide 5 contained an overhang that complemented the BsmI end of the pNN03-applaggin fragment (5'-CG-3'). After synthesis, the oligonucleotides were treated with T4 kinase in the presence of ATP to add a phosphate group onto the 5' ends. We then heated all six oligonucleotides together to 90°C and allowed the solution to slowly cool to room temperature in order to anneal the complementary strands and the complementary overhangs. We then assembled the Met-N-appilog gene by ligating the annealed oligonucleotides (3.3 pmoles)

- 44 -

together with approximately 200 ng of the large BsmI/NcoI fragment from pNN03-applaggin.

To construct the Met-C-appilog gene, 21.8 ng of pNN03-applaggin was digested with 40 units of PstI.
5 We then adjusted the NaCl concentration up to 50 mM, added 40 units of HindIII and continued digestion at 37°C for an additional 2 hours. We electrophoresed the digestion mixture on a 0.7% agarose gel and visualized the bands with ethidium bromide. The large fragment
10 was then excised and electroeluted. We synthesized the portion of the gene coding for the thrombin inhibitory domain of Met-C-appilog as 3 pairs of complementary oligonucleotides containing 5' and 3' overhangs for complementary assembly (Figure 6). Additionally,
15 oligonucleotide 2 contained an overhang that complemented the PstI end of the fragment from pNN03-applaggin (ACGT), while oligonucleotide 6 contained an overhang that complemented the HindIII end of the pNN03-applaggin fragment (TCGA). The oligonucleotides
20 were kinased and annealed as described previously. The Met-C-appilog gene was assembled by ligating 3.3 pmoles of the annealed oligonucleotides together with 200 ng the large PstI/HindIII fragment from pNN03-applaggin.

The Met-N- and Met-C-appilog ligation
25 products were then used to separately transform E. coli JA221 cells which were then plated on LB agar + ampicillin (100 µg/ml) plates. Plasmids from several colonies were isolated and analyzed by restriction enzyme analysis and DNA sequencing. We used plasmid
30 pNN0-C-appilog #7 and pNN0-N-appilog #7 for further manipulations.

EXAMPLE 2

Construction Of OmpA-Appilog Expression Vectors

- 45 -

The plasmid vector pIN-III-ompA1, which has been previously described [J. Ghrayeb et al., "Secretion Cloning Vectors in Escherichia coli", EMBO J., 3, pp. 2437-42 (1984)], allows fusion of protein
5 coding sequences to the signal sequence of outer membrane protein A (OmpA). The ompA signal sequence is capable of directing export of proteins across the bacterial inner membrane into the periplasm.

Initially, we digested approximately 10 μ g
10 each of plasmid pNNO-C-appilog #7 and pNNO-N-appilog #7 with 20 units of NcoI. The digestion product was purified by phenol/chloroform extraction, followed by Na acetate/ ethanol precipitation. The digestion product was then blunt-ended to remove the resulting
15 overhangs by digestion with 10 units Mung Bean Nuclease [Pharmacia-LKB, Piscataway, NJ] for 10 minutes at 37°C in 30 mM Na acetate, 50 mM NaCl, 1 mM ZnCl, pH 4.6. Following digestion, we added EDTA to a final concentration of 10 mM. The DNA was then extracted
20 with phenol/chloroform and Na acetate/ethanol precipitated. Each of the vectors was then cleaved with 100 units of HindIII. The 300 bp fragment of Met-C-appilog or Met-N-appilog was then purified by agarose gel electrophoresis on a 1% gel, followed by excision
25 of the band and electroelution of the DNA into dialysis bags at 50 volts for 30 minutes. The DNA was the concentrated by ethanol precipitation.

We digested 10 μ g of vector pIN-III-ompA1 with 20 units of EcoRI. The digestion product was
30 blunt-ended with Mung Bean nuclease as previously described. We then cleaved the vector with 100 units of HindIII to release a 7.5 kb fragment. We electrophoresed the digestion mixture on a 1% agarose gel and excised the 7.5 kb fragment. The DNA was

- 46 -

electroeluted into a dialysis bag and purified by ethanol precipitation.

We then ligated 40 ng of the 300 bp appilog DNA fragment (from Met-C- or Met-N-appilog) to 200 ng of the 7.5 kb pIN-III-ompA vector fragment with T4 ligase. We then transformed E. coli strain JA221^{lacIq} with the ligation mixture and plated transformants on LB agar + ampicillin (100 µg/ml). Colonies were screened for the presence of the desired plasmid by colony hybridization with the ³²P-labeled, 400 base pair NcoI-PvuII fragment of pNNO-N-appilog #7, which contained the N-appilog gene. Positive colonies were picked and grown overnight in 5 ml of LB broth + ampicillin (100 µg/ml). We took 0.1 ml of the overnight culture and inoculated into 5 ml of fresh media. The cultures were grown for 4 hours at 37°C. We then added 1 mM IPTG to the cultures to induce appilog expression and continued incubation for 2 hours. We centrifuged 1 ml of the induced culture and resuspended the cell pellet in 100 µl of SDS-PAGE loading buffer. The sample was boiled for 5 minutes and loaded onto a 16% polyacrylamide-SDS gel. After running the gel, the proteins were transferred to nitrocellulose paper and screened for the expression of appilog protein by Western Blot analysis using rabbit anti-applaggin antibodies. No colonies expressed any polypeptides which reacted positively in the Western Blot. DNA sequence analysis of one of the clones containing the Met-C-appilog gene, pIN-III-ompA1-CAPLG-B5, revealed that the expected junction between the ompA signal sequence and the appilog coding sequences was incorrect and therefore the C-appilog sequence was not in frame with the ompA signal sequence.

We therefore attempted a second strategy for cloning the appilog gene into pIN-III-ompA1. This

- 47 -

scheme is depicted in Figure 7. We cleaved pIN-III-ompA1 with EcoRI and HindIII as described above and purified the large, 7.5 kilobase (kb) fragment by agarose gel electrophoresis on a 1% gel, followed by

5 excision of the fragment, electroelution and ethanol precipitation. We next cleaved 10 µg of pIN-III-ompA1-CAPLG-B5 simultaneously with 24 units of BamHI and 20 units HindIII to release a 270 bp fragment containing all of the Met-C-appilog gene except for approximately

10 the first 30 nucleotides (the BamHI site spans the codons for Gly-Ser at amino acids 9 and 10). The resulting fragment was gel purified and electroeluted as previously described. We then synthesized a pair of partially complementary oligonucleotides which, when

15 inserted between the EcoRI site of the pIN-III-ompA1 fragment and the BamHI site of the C-appilog gene, built back the missing portion of the C-appilog coding region and kept the appilog gene in frame with the ompA signal sequence. These oligonucleotides had the

20 sequence (SEQ ID NO:12):
5'-AATTCGGAAGCTGGTGAAGAATGCGACTGCG-3'; and (SEQ ID NO:13): 5'-GATCCGCAGTCGCATTCTCACCAGCTTCCG-3'. The resulting gene coded for an ompA signal sequence-Ala-Asn-Ser-C-appilog fusion protein.

25 We boiled the 20 pmoles of each of the above oligonucleotides for 2 minutes and allowed the solution to slowly cool to room temperature to effect annealing. We then ligated together 200 ng of the 7.5 kb fragment from pIN-III-ompA1, 40 ng of the 270 bp BamHI-HindIII

30 fragment of pIN-III-ompA1-CAPLG-B5 and 5 pmoles of the annealed oligonucleotides with T4 ligase and used the ligation mixture to transform JA221^{lacIq} cells. Transformants were grown on LB agar + ampicillin (100 µg/ml). Plasmid DNA from random colonies was

35 prepared and analyzed by digestion with EcoRI to show

- 48 -

that the desired junction between the ompA signal sequence and the synthetic oligonucleotides was generated. Clones containing the correct construction are linearized by digestion with EcoRI. DNA sequencing
5 of one positive plasmid, pCAPLG-C21, confirmed the presence of the correct sequence. This construct coded for the ompA signal sequence, followed by Ala-Asn-Ser-C-appilog.

An alternate strategy for the cloning of the
10 N-appilog gene into pIN-III-ompA1 is depicted in Figure 8. Specifically, we digested 10 µg of pBR322 simultaneously with 20 units of EcoRI and 20 units HindIII. We then purified the large 4,322 bp fragment by gel electrophoresis on a 1% agarose gel, excision of
15 the band, electroelution of the DNA and ethanol precipitation. The plasmid pNNO-N-appilog #7 (10 µg) was cleaved with 40 units of BstBI at 65°C for 2 hours under mineral oil. We then added 20 units of HindIII to the digestion mixture and incubated at 37°C for an
20 additional 2 hours. This digestion released a 249 bp fragment containing the C-terminal coding region of N-appilog (BstBI cleaves between the codons for amino acids 11 and 12 of the polypeptide).

We then synthesized a pair of partially
25 complementary oligonucleotides which could be inserted between the EcoRI end of pBR322 and the BstBI end of the N-appilog gene and would regenerate the first 12 amino acids of N-appilog. The oligonucleotides had the nucleotide sequences (SEQ ID NO:14):

30 5'-AATTCGGGTCCGCGTCCGGGTGGTGGTAAACGGTGACTT-3'; and
(SEQ ID NO:15):

5'-CGAAGTCACCGTTACCACCACCACCCGGACGGGACCCG-3'.

The resulting gene coded for an ompA signal sequence-Ala-Asn-Ser-N-appilog fusion protein.

- 49 -

We annealed 20 pmoles of each oligonucleotide as previously described. We then ligated together 200 ng of the pBR322 fragment, 40 ng of the N-appilog gene fragment and 5 pmoles of the annealed

- 5 oligonucleotides with T4 ligase and transformed E. coli strain DH5-alpha with the ligation mixture.

Transformants were plated on LB agar + ampicillin (100 µg/ml). Individual colonies were picked and plasmids purified therefrom by the alkaline miniprep technique.

- 10 The plasmids from random transformants were analyzed by EcoRI/HindIII digestion to identify those releasing an approximately 305 bp fragment. DNA sequencing of one of these positive plasmids, pBR322-NAPLG-3.1, confirmed the presence of the correct coding sequence for Ala-
15 Asn-Ser-N-appilog.

We next grew up a large culture (1 liter) of pBR322-NAPLG-3.1 in LB + ampicillin and prepared plasmid therefrom by the alkaline lysis technique. The resulting plasmid preparation was further purified by
20 CsCl gradient centrifugation. We digested 10 µg of the resulting plasmid with 20 units each of EcoRI/HindIII and isolated the 305 base pair fragment by agarose gel electrophoresis and electroelution. We then ligated the 40 ng of the fragment to 200 ng of the large

- 25 EcoRI/HindIII fragment of pIN-III-ompA1.

EXAMPLE 3

Expression And Purification Of OmpA-Appilog Expression Products

- A fresh colony of pCAPLG-C21 was picked and
30 grown overnight at 37°C in 10 ml of M-9 media supplemented with 4 mg/ml glucose, 50 µg/ml each of tryptophan, leucine and ampicillin, 2 µg/ml thiamine and 2 mg/ml casamino acids. We then inoculated the overnight culture into 1 liter of the same supplemented

- 50 -

M-9 media and grew the culture at 37°C on a shaker until the cells reached a density of 0.4 OD₅₅₀. We then added 2 mM IPTG to the culture to induce the cells and continued growth for an additional 3 hours.

5 The cells were then harvested by centrifugation at 4,000 x g and the cell pellets were resuspended in 20 ml of cold 20 mM Tris, 1 mM EDTA containing 10 mg PMSF. The suspension was passed twice through a French Press at 1,000 PSI. The soluble cell
10 extract was collected by centrifuging the suspension at 10,000 rpm in an SS34 rotor (Sorval) for 30 minutes at 4°C. The supernatant was precipitated with 40% ammonium sulfate at 4°C overnight. The ammonium sulfate pellet was isolated by centrifugation and
15 redissolved in 15 ml of 20 mM Tris-HCl, 1 mM EDTA, pH 7.5. We then chromatographed this solution over a G-50 column (2.75 x 100 cm) at 4°C in the same buffer. Fractions (7 ml) were collected and aliquots (10 µl) were assayed by Western Blot analysis using rabbit
20 anti-applaggin antibodies (1:1,000 dilution). C-appilog-containing fractions were pooled and further purified by reverse phase HPLC on a C8 column (0.25 x 10 cm). The column was eluted with a linear gradient of 0 to 50% solution B (70% acetonitrile in 0.085% TFA)
25 over 45 minutes at a flow rate of 1 ml/min.

Fractions were monitored by (absorbance at 214 and 280 nm). C-appilog containing fractions were pooled and subjected to partial amino acid sequence analysis. The 15 N-terminal amino acids were
30 determined to be Ala-Asn-Ser-Glu-Ala-Gly-Glu-Glu-?-Asp-?-Gly-Ser-Pro-Glu, confirming proper construction. The presence of Ala-Asn-Ser at the N-terminus of this C-appilog was expected based on the oligonucleotide linkers used in vector construction.

- 51 -

Construction Of Male-Appilog Expression Vectors

Vectors comprising a Met-C-appilog or Met-N-appilog fused to the 3' end of the male gene were constructed in both the pMAL-c (a vector containing the male gene without its native signal sequence) and pMAL-p (a vector containing the male gene together with the native signal sequence) plasmids as depicted in Figure 9 (New England Biolabs).

Specifically, 10 µg of either pNNO-C-appilog #7 or pNNO-N-appilog #7 (as described in Example 1) were digested with 20 units of NcoI, phenol/chloroform extracted and ethanol precipitated. We then filled in the resulting 5' overhang with 5 units of the Klenow fragment of DNA polymerase I and a mixture of dinucleotidetriphosphates (dNTPs) for 30 minutes at 25°C. The plasmid was then digested with 20 units of HindIII to release a 300 bp fragment containing the appilog gene. The NcoI-HindIII fragment was isolated by agarose gel electrophoresis, electroelution, and ethanol precipitation.

We digested either pMAL-c or pMAL-p with 20 units of EcoRI. We then extracted, precipitated and treated the digestion product with Klenow fragment, as described above. We next digested the blunt-ended DNA with 20 units of HindIII. The large fragment was isolated from an agarose gel, electroeluted and ethanol precipitated. The purified NcoI-HindIII fragment of either pNNO-C-appilog or pNNO-N-appilog (40 ng) was mixed with the 200 ng of the EcoRI-HindIII fragment from pMAL-c or pMAL-p (4 different constructions in total) and ligated with T4 ligase. We transformed E. coli DH5-alpha cells with the ligated DNA and grew the transformants on LB agar + ampicillin (100 µg/ml) + XG

- 52 -

(5-Bromo-4-Chloro-3-Indolyl-galactopyranoside,
40 μ g/ml).

We purified 6 white colonies from each ligation and isolated plasmid DNA from each by the alkaline miniprep procedure. We digested each of the plasmids with NcoI and HindIII and ran the digestion mixtures on an agarose gel. Those plasmids releasing an approximately 500 bp fragment were assumed to contain appilog gene inserts. In this manner plasmids pMAL-c-CAPLG (C-appilog insert), pMAL-p-CAPLG, pMAL-c-NAPLG (N-appilog insert), and pMAL-p-NAPLG were isolated. From each construction, at least 5 out of 6 analyzed plasmids contained the expected appilog gene insert. The expected DNA and protein sequence at the Male-appilog junction is shown in Figure 10.

EXAMPLE 5

Expression And Detection Of Male-Appilog Fusion Proteins

Two transformants from each construction (i.e, containing plasmids pMAL-c-CAPLG pMAL-p-CAPLG, pMAL-c-NAPLG or pMAL-p-NAPLG) were separately grown in LB medium + ampicillin (100 μ g/ml) at 37°C overnight. We then diluted 0.1 ml of the overnight culture into the 5 ml of the same medium supplemented with 1 mM IPTG and incubated at 37°C for 4 hrs. We isolated cells from 1 ml of culture by centrifugation, resuspended them in 100 μ l of SDS-PAGE loading buffer, and boiled for 3 minutes. We loaded 5 μ l of this sample onto a 10% SDS-polyacrylamide gel for electrophoresis. Protein gels were either stained with Coomassie Blue or electroblotted to nitrocellulose and probed with antibody to applaggin in a standard Western Blot immunodetection assay. The positive protein bands were visualized using anti-rabbit IgG conjugated to

- 53 -

horseradish peroxidase or alkaline phosphatase and the appropriate colorimetric reagent. All of the assayed transformants produced a detectable protein by Western Blot, confirming that each construction directed the
5 expression of an appilog polypeptide.

EXAMPLE 6

Purification Of MalE-Appilog Fusion Proteins And Isolation Of Appilog By Factor Xa Digestion

One of the positive pMAL-c-CAPLG clones was
10 used for larger scale purification of the appilog-containing polypeptide. We grew an overnight culture of this clone in LB media + ampicillin (100 μ g/ml). We inoculated 1 liter of LB + ampicillin (50 μ g/ml) with 10 ml of the overnight culture and grew the large
15 culture at 37°C until they reached an OD₅₅₀ of 0.4. We then induced appilog expression by adding IPTG to the culture to a final concentration of 0.3 mM and reincubating at 37°C for 2 hours. The cells were then harvested by centrifugation at 4,000 x g for 20
20 minutes. The cell pellet was resuspended in 50 ml of lysis buffer (10 mM sodium phosphate, 30 mM NaCl, 0.25% Tween-20, 10 mM β -mercaptoethanol, 10 mM EDTA, 10 mM EGTA, pH 7.0) and the cells then broken open by 2 passages through a French Press at 2,000 psi. We next
25 added NaCl to the solution to a final concentration of 0.5 M and then centrifuged at 9,000 x g for 30 minutes. The resulting crude extract was diluted 1:5 with column buffer (10 mM sodium phosphate, 500 mM NaCl, 10 mM β -mercaptoethanol, 1 mM Na azide, 10 mM EGTA, pH 7.0) +
30 0.25% Tween-20 for loading onto an amylose resin column.

The diluted extract was applied to a 40 ml amylose resin (New England Biolabs) column at a flow rate of 1 ml/min. After loading the sample, the column

- 54 -

was washed with 3 column volumes of column buffer containing 0.25% Tween-20 and 5 column volumes of column buffer without Tween-20. The maltose binding protein-containing appilog polypeptide was eluted with
5 column buffer containing 10 mM maltose. Elution was monitored by absorbance at 280 nm. The polypeptide eluted soon after the void volume of the column.

The appilog-containing fractions were pooled and dialyzed overnight against 4 changes of 100 volumes
10 each of 10 mM Tris-HCl, 100 mM NaCl, 2 mM CaCl₂, pH 8. Following dialysis, we adjusted the protein concentration to 1 mg/ml and added 20 units of Factor Xa [New England Biolabs]. Digestion was allowed to proceed overnight at room temperature.

15 After Factor Xa cleavage, the digestion products were purified by HPLC on a C8 reverse phase column (4.6 x 10 cm). The column was developed with a linear gradient of increasing acetonitrile (0 - 60%) in 0.1% TFA over 54 minutes at a flow rate of 1 ml/minute.
20 The appilog polypeptide eluted at 23% acetonitrile concentration, prior to the MBP polypeptide. Automated Edman degradation of the purified appilog polypeptide revealed an N-terminal sequence of Gly-Ser-Ile-Glu-Gly-Arg-Pro-Glu-Phe-Met, indicating that Factor Xa had
25 cleaved at an Arg-Gly bond in the fusion protein. The resulting appilog polypeptide was referred to as Gly-Ser-Ile-Glu-Gly-Arg-Pro-Glu-Phe-Met-C-appilog. The cytoplasmic malE-N-appilog fusion protein is similarly purified and has an identical N-terminal amino acid
30 sequence.

A similar series of steps is used to purify and cleave the fusion protein produced from the pMAL-p-appilog constructs. The only difference being that the expressed fusion protein is initially obtained by

- 55 -

osmotic shock of the transformed E. coli, instead of cell lysis.

EXAMPLE 7

Other Appilog Constructs

5 The malE-appilog constructs described in Example 4 can be modified to allow Factor Xa cleavage at a site nearer to the amino terminus of C- or N-appilog and to allow the resulting appilog to have a shorter N-terminal extension. This is achieved by
10 changing the Ile-Glu-Gly-Arg-Pro-Glu-Phe-Met sequence to Ile-Glu-Gly-Arg-Ile-Met. The first four amino acids of the latter sequence is the native Factor Xa cleavage site present in bovine prothrombin [K. Nagai et al.,
15 Nature, 309, pp. 810-12 (1984)]. Factor Xa cleaves this sequence in between the Arg and Ile residue, producing an Ile-Met-appilog. Similarly, if the sole methionine residue present within the appilog portion of the malE-appilog fusion protein is changed to another amino acid, cyanogen bromide cleavage of the
20 fusion protein will produce an appilog polypeptide containing no N-terminal extensions.

To effect these changes, a single DNA sequence encoding both of these modified regions is synthesized by the polymerase chain reaction (PCR).
25 This new DNA sequence is then substituted for the corresponding region contained in the original malE-appilog construct.

Figure 11 depicts the scheme for making these changes in pMAL-c-CAPLG. Specifically, we first
30 synthesize two primers to be used in the PCR procedure. These are (SEQ ID NO:16):
5'-ACGTCGGTACCAGGCGCGCGTATCGAGGGTAGGATCATGGAAGCTGGTGAA-
3', which incorporates the Pro-Glu-Phe-Met to Ile-Met change; and (SEQ ID NO:17):

- 56 -

5'-GCAAACGGTACCTTCTTTCAGGAATTTGCACTGGTC-3', which incorporates the conservative Met to Leu change at amino acid 41 of C-appilog. The primers are then used in PCR amplification techniques employing a

5 Cetus/Perkin-Elmer PCR apparatus and following the manufacturer's directions.

The resulting amplified 180 base pair fragment contains KpnI sites at both ends. Following PCR, the fragment is purified and cleaved with KpnI.

10 Plasmid pMAL-c-CAPLG is also cleaved with KpnI. This removes the fragment corresponding to the PCR synthesized fragment from the vector. The large 6kb KpnI fragment of pMAL-c-CAPLG is then purified by agarose gel electrophoresis and electroelution. We

15 then ligate the large KpnI fragment of pMAL-c-CAPLG to the KpnI cleaved 180 base pair PCR fragment and use the ligation product to transfect E. coli DH5-alpha cells by the method described in Example 4. Detection of clones containing the proper construct and expressing

20 the desired fusion protein is achieved by the methods described in Examples 4 and 5, respectively. Large scale expression, purification and Factor Xa cleavage of the malE-appilog fusion protein is carried out according to the protocol set forth in Example 6. The

25 end product of this procedure is Ile-Met-C-appilog(Leu₄₁). If the purified fusion protein is treated with cyanogen bromide instead of Factor Xa, the resulting product, which is subsequently purified by reverse phase HPLC, is C-appilog(Leu₄₁). The same

30 protocol may be used to alter pMAL-p-CAPLG.

A similar series of steps may be carried out with pMAL-c-NAPLG or pMAL-p-NAPLG. When using either of these vectors, the oligonucleotide primer spanning the Factor Xa cleavage site must be constructed based on

35 the N-terminal sequence of N-appilog. The internal

- 57 -

oligonucleotide will be the same as that used for pMAL-c-CAPLG (SEQ ID NO:17). It will be apparent that the amplified fragment will be approximately 72 bases longer, because the location of the methionine residue in N-appilog is at amino acid 65. The end product of Factor Xa digestion in these constructs is termed Ile-Met-N-appilog(Leu)₆₅. The cyanogen bromide cleaved expression product of these constructs is termed N-appilog(Leu)₆₅.

10

EXAMPLE 8

Anticoagulant Activity Of
Gly-Ser-Ile-Glu-Gly-Arg-Pro-Glu-Phe-Met-C-Appilog

We compared the anticoagulant activities of L-Phe-Hirulog-8 (SEQ ID NO:18; Phe-Pro-Arg-Pro-Gly-Gly-Gly-Gly-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu, a peptide equivalent to the thrombin inhibitory domain of the bifunctional inhibitors of this invention), applaggin, an equimolar combination of L-Phe-Hirulog-8 and applaggin, and Gly-Ser-Ile-Glu-Gly-Arg-Pro-Glu-Phe-Met-C-appilog using pooled, normal human plasma (George King Biomedical, Overland Park, KA) and a Coag-A-Mate XC instrument (General Diagnostics, Organon Technica, Oklahoma City, OK). Activity was monitored using the activated partial thromboplastin time (APTT) assay with CaCl₂ and phospholipid solutions obtained from the manufacturer. The various inhibitors were then added to separate APTT determination wells at final concentrations of 0 to 10 μ M in a total volume of 25 μ l prior to addition of 100 μ l of plasma.

The control APTT (absence of inhibitor) was 32 seconds. Figure 12 shows the results of these dose-dependency studies. This study showed that APTT was increased by Gly-Ser-Ile-Glu-Gly-Arg-Pro-Glu-Phe-Met-

- 58 -

C-appilog in a dose-dependent manner. Figure 12 also shows that Gly-Ser-Ile-Glu-Gly-Arg-Pro-Glu-Phe-Met-C-appilog increased APTT by a greater amount than any of the other 2 inhibitors, either alone or in combination.

- 5 Other appilogs of this invention may be assayed in a similar manner and will show a similar dose-dependent increase in APTT.

EXAMPLE 9

Inhibition Of Platelet Aggregation And Release

- 10 We prepared platelet-rich plasma from healthy human volunteers for use in various platelet assays. More specifically, blood was collected via a 21 gauge butterfly cannula, using a two-syringe technique, into 1/10 volume of 3.8% trisodium citrate. Platelet-rich
15 plasma was prepared by room temperature centrifugation of the citrated whole blood for 15 minutes at 100 x g. The platelet rich plasma contained approximately 357,000 platelets/ μ l. We prepared platelet-poor plasma by centrifuging the citrated whole blood for 2 minutes
20 at 12,000 x g.

- Platelet aggregation was assayed in a 4-channel platelet aggregation profiler (PAP4, Biodata, Hatboro, Pennsylvania) according to the manufacturer's directions. We studied inhibition of platelet
25 aggregation effected by Gly-Ser-Ile-Glu-Gly-Arg-Pro-Glu-Phe-Met-C-appilog by adding varying amounts (0 - 2 μ M, final concentration) of the polypeptide to stirred human platelet-rich plasma. Specifically, we incubated the appilog with the 0.45 ml of platelets for
30 1 minute at 37°C prior to the addition of collagen (60 μ g/ml) Figure 13 demonstrates that Gly-Ser-Ile-Glu-Gly-Arg-Pro-Glu-Phe-Met-C-appilog inhibited platelet aggregation induced by collagen in a dose-dependent manner.

- 59 -

To assay the effect of this appilog on the inhibition of thrombin-induced platelet aggregation, we first gel filtered the above platelet preparation using procedures described by B. Chao et al., Proc. Natl. Acad. Sci. USA, 86, pp. 8050-54 (1989). We performed the assay as above, using appilog in a range of 0 - 0.2 μ M in the presence of 0.4 units/ml thrombin. We compared the inhibitory effect of this appilog to equimolar concentrations of applaggin; L-Phe-Hirulog-8; and an equimolar combination of applaggin and L-Phe-Hirulog-8. Figure 14 depicts the result of this dose-dependency study. As with collagen, Gly-Ser-Ile-Glu-Gly-Arg-Pro-Glu-Phe-Met-C-appilog inhibited thrombin-induced platelet aggregation in a dose-dependent manner. Moreover, at 0.1 and 0.2 μ M concentrations, appilog demonstrated superior inhibition of platelet aggregation over the combination of applaggin and L-Phe-Hirulog-8. Other appilogs of this invention are similarly assayed for the ability to inhibit platelet aggregation and display similar inhibitory activity.

The ability of appilog to inhibit the release of 14 C-serotonin from platelets is also measured. Platelets in a plasma suspension are loaded with [14 C]-serotonin (Amersham, Arlington Heights, Illinois) by incubation at 37°C for 30 minutes. Following this treatment, platelets are gel filtered. Stirred [14 C]-serotonin loaded platelets in Tyrode-HEPES buffer (0.5 ml) are incubated at 37°C with varying amounts of appilog, applaggin or L-Phe-Hirulog-8. Platelets are then stimulated by the addition of 0.4 units of thrombin. At varying times after the addition of thrombin (0 - 30 minutes), the reaction is terminated and serotonin release and reuptake blocked by the addition of a 1/10th volume of ice-cold ETPI cocktail (3.3% EDTA, 10 mM theophylline, 1 μ g/ml prostaglandin

- 60 -

- E1 and 500 μ M imipramine). Following the addition of ETPI, platelets are recovered by centrifugation at 12,000 x g for 2 minutes. Release is measured by liquid scintillation counting of [14 C]-radioactivity.
- 5 At concentrations of 0.5 μ M, appilog strongly inhibits serotonin release over the full 30 minute course of the investigation, while applaggin demonstrates no significant effect on the platelet release reaction. At the same molar concentration, L-Phe-Hirulog-8
- 10 inhibits serotonin release, but to a lesser extent than the appilog.

EXAMPLE 10

Inhibition Of Metastatic Cell Growth By Appilogs

- The anti-metastatic activity of the
- 15 bifunctional inhibitors of this invention, preferably an appilog, is assayed using sarcoma T241 cells [L. A. Liotta et al., Nature, 284, pp. 67-68 (1980)] and syngeneic C57BL/6 mice (Jackson Laboratory, Bar Harbor, ME). The mice are injected either intravenously or
- 20 subcutaneously with 0 - 250 g/kg of appilog, followed by injection with 10^4 - 10^6 T241 tumor cells. After 15 days, the animal is sacrificed and lung tumor colonies are quantitated. Anti-metastatic activity of appilog is measured as percent reduction in tumor colonies
- 25 compared to placebo-treated control mice. Appilogs demonstrate anti-metastatic activity in this assay.

- In an alternative assay, aliquots of human melanoma cells ($1 - 5 \times 10^6$ cells) are treated with varying amounts (0 - 50 μ g/ml) of appilog. The cells
- 30 are then grafted onto the subcutaneous, ventral surface of nude mice.

The mice which receive appilog-treated cells are given two daily subcutaneous injections of appilog (0.1 mg/kg). Control mice, which are grafted with

- 61 -

untreated cells, are given subcutaneous injections of saline twice daily. Tumor growth in both experimental and control mice is monitored over a 30 day period by measurement of the tumor mass. The experimental mice
5 display smaller tumors than the control mice at the end of the 30 day period.

EXAMPLE 11

Effect Of A Combination Of tPA And Appilog On Thrombolysis

10 A rat model for arterial thrombolysis is used to determine the effect of appilog on potentiating tPA-induced thrombolysis. In this model, an experimental thrombus is formed in the abdominal aorta following balloon catheter denudation and high grade (95%)
15 stenosis. Blood flow and blood pressure are recorded distal to the site of injury and stenosis. Test animals are randomized to receive tPA (1.0 mg/kg bolus followed by 1.0 mg/kg/hr infusion) together with saline or appilog (0.6 mg/kg bolus followed by
20 0.02 mg/kg/hr infusion). The appilog or saline is administered concomitant with tPA and for an additional 50 minutes following the end of tPA infusion.

Animals treated with tPA + appilog exhibit significantly lower reperfusion times, greater
25 reocclusion times and greater times of vessel patency than animals treated with tPA + saline. Therefore appilogs may be used to increase the efficacy of tPA. Moreover, compositions comprising appilog together with tPA may advantageously contain tPA at lower than
30 conventional dosages without sacrificing efficacy. The use of such lower quantities of tPA reduces the risk of side effects associated with tPA administration.

While we have hereinbefore presented a number of embodiments of this invention, it is apparent that

- 62 -

our basic construction can be altered to provide other embodiments which utilize the molecules, compositions, combinations and methods of this invention. Therefore, it will be appreciated that the scope of this invention

5 is to be defined by the claims appended hereto rather than the specific embodiments which have been presented hereinbefore by way of example.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: Biogen, Inc.

(ii) TITLE OF INVENTION: BIFUNCTIONAL INHIBITORS OF THROMBIN AND
PLATELET ACTIVATION

(iii) NUMBER OF SEQUENCES: 14

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Fish & Neave
(B) STREET: 875 Third Avenue - 29th Floor
(C) CITY: New York
(D) STATE: New York
(E) COUNTRY: United States
(F) ZIP: 10022

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.24

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:

(vii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Haley Jr., James F.
(B) REGISTRATION NUMBER: 27,794
(C) REFERENCE/DOCKET NUMBER: B154

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (212) 715-0600
(B) TELEFAX: (212) 715-0674
(C) TELEX: 14-8367

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 72 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

- 64 -

Glu Ala Gly Glu Glu Cys Asp Cys Gly Ser Pro Glu Asn Pro Cys Asp
 1 5 10 15
 Asp Ala Ala Thr Cys Lys Leu Arg Pro Gly Ala Gln Cys Ala Glu Gly
 20 25 30
 Leu Cys Cys Asp Gln Cys Lys Phe Xaa Lys Glu Gly Thr Val Cys Arg
 35 40 45
 Arg Ala Arg Gly Asp Asp Val Asn Asp Tyr Cys Asn Gly Ile Ser Ala
 50 55 60
 Gly Cys Pro Arg Asn Pro Phe His
 65 70

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 96 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Gly Pro Arg Pro Gly Gly Gly Asn Gly Asp Phe Glu Glu Ile Pro
 1 5 10 15
 Glu Glu Tyr Leu Gly Gly Gly Gly Glu Ala Gly Glu Glu Cys Asp Cys
 20 25 30
 Gly Ser Pro Glu Asn Pro Cys Asp Asp Ala Ala Thr Cys Lys Leu Arg
 35 40 45
 Pro Gly Ala Gln Cys Ala Glu Gly Leu Cys Cys Asp Gln Cys Lys Phe
 50 55 60
 Xaa Lys Glu Gly Thr Val Cys Arg Arg Ala Arg Gly Asp Asp Val Asn
 65 70 75 80
 Asp Tyr Cys Asn Gly Ile Ser Ala Gly Cys Pro Arg Asn Pro Phe His
 85 90 95

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 96 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(x1) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Glu	Ala	Gly	Glu	Glu	Cys	Asp	Cys	Gly	Ser	Pro	Glu	Asn	Pro	Cys	Asp
1				5					10					15	
Asp	Ala	Ala	Thr	Cys	Lys	Leu	Arg	Pro	Gly	Ala	Gln	Cys	Ala	Glu	Gly
			20					25					30		
Leu	Cys	Cys	Asp	Gln	Cys	Lys	Phe	Xaa	Lys	Glu	Gly	Thr	Val	Cys	Arg
		35					40					45			
Arg	Ala	Arg	Gly	Asp	Asp	Val	Asn	Asp	Tyr	Cys	Asn	Gly	Ile	Ser	Ala
	50					55					60				
Gly	Cys	Pro	Arg	Asn	Pro	Phe	His	Gly	Gly	Gly	Gly	Gly	Pro	Arg	Pro
65					70					75					80
Gly	Gly	Gly	Gly	Asn	Gly	Asp	Phe	Glu	Glu	Ile	Pro	Glu	Glu	Tyr	Leu
				85					90						95

(2) INFORMATION FOR SEQ ID NO:4:

(1) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 106 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(11) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Gly	Ser	Ile	Glu	Gly	Arg	Pro	Glu	Phe	Met	Gly	Pro	Arg	Pro	Gly	Gly
1			5						10					15	
Gly	Gly	Asn	Gly	Asp	Phe	Glu	Glu	Ile	Pro	Glu	Glu	Tyr	Leu	Gly	Gly
		20						25					30		
Gly	Gly	Glu	Ala	Gly	Glu	Glu	Cys	Asp	Cys	Gly	Ser	Pro	Glu	Asn	Pro
		35					40					45			
Cys	Asp	Asp	Ala	Ala	Thr	Cys	Lys	Leu	Arg	Pro	Gly	Ala	Gln	Cys	Ala
	50					55					60				
Glu	Gly	Leu	Cys	Cys	Asp	Gln	Cys	Lys	Phe	Met	Lys	Glu	Gly	Thr	Val
65					70					75					80
Cys	Arg	Arg	Ala	Arg	Gly	Asp	Asp	Val	Asn	Asp	Tyr	Cys	Asn	Gly	Ile
			85						90					95	

Ser Ala Gly Cys Pro Arg Asn Pro Phe His
100 105

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 99 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Ala Asn Ser Gly Pro Arg Pro Gly Gly Gly Gly Asn Gly Asp Phe Glu
1 5 10 15
 Glu Ile Pro Glu Tyr Leu Gly Gly Gly Gly Glu Ala Gly Glu Glu
20 25 30
 Cys Asp Cys Gly Ser Pro Glu Asn Pro Cys Asp Asp Ala Ala Thr Cys
35 40 45
 Lys Leu Arg Pro Gly Ala Gln Cys Ala Glu Gly Leu Cys Cys Asp Gln
50 55 60
 Cys Lys Phe Met Lys Glu Gly Thr Val Cys Arg Arg Ala Arg Gly Asp
65 70 75 80
 Asp Val Asn Asp Tyr Cys Asn Gly Ile Ser Ala Gly Cys Pro Arg Asn
85 90 95
 Pro Phe His

(2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 98 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Ile Met Gly Pro Arg Pro Gly Gly Gly Gly Asn Gly Asp Phe Glu Glu
1 5 10 15
 Ile Pro Glu Glu Tyr Leu Gly Gly Gly Gly Glu Ala Gly Glu Glu Cys
20 25 30

- 67 -

Asp Cys Gly Ser Pro Glu Asn Pro Cys Asp Asp Ala Ala Thr Cys Lys
 35 40 45

Leu Arg Pro Gly Ala Gln Cys Ala Glu Gly Leu Cys Cys Asp Gln Cys
 50 55 60

Lys Phe Leu Lys Glu Gly Thr Val Cys Arg Arg Ala Arg Gly Asp Asp
 65 70 75 80

Val Asn Asp Tyr Cys Asn Gly Ile Ser Ala Gly Cys Pro Arg Asn Pro
 85 90 95

Phe His

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 106 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Gly Ser Ile Glu Gly Arg Pro Glu Phe Met Glu Ala Gly Glu Glu Cys
 1 5 10 15

Asp Cys Gly Ser Pro Glu Asn Pro Cys Asp Asp Ala Ala Thr Cys Lys
 20 25 30

Leu Arg Pro Gly Ala Gln Cys Ala Glu Gly Leu Cys Cys Asp Gln Cys
 35 40 45

Lys Phe Met Lys Glu Gly Thr Val Cys Arg Arg Ala Arg Gly Asp Asp
 50 55 60

Val Asn Asp Tyr Cys Asn Gly Ile Ser Ala Gly Cys Pro Arg Asn Pro
 65 70 75 80

Phe His Gly Gly Gly Gly Gly Pro Arg Pro Gly Gly Gly Gly Asn Gly
 85 90 95

Asp Phe Glu Glu Ile Pro Glu Glu Tyr Leu
 100 105

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 99 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

```

Ala Asn Ser Glu Ala Gly Glu Glu Cys Asp Cys Gly Ser Pro Glu Asn
1           5           10           15
Pro Cys Asp Asp Ala Ala Thr Cys Lys Leu Arg Pro Gly Ala Gln Cys
20           25           30
Ala Glu Gly Leu Cys Cys Asp Gln Cys Lys Phe Met Lys Glu Gly Thr
35           40           45
Val Cys Arg Arg Ala Arg Gly Asp Asp Val Asn Asp Tyr Cys Asn Gly
50           55           60
Ile Ser Ala Gly Cys Pro Arg Asn Pro Phe His Gly Gly Gly Gly Gly
65           70           75           80
Pro Arg Pro Gly Gly Gly Gly Asn Gly Asp Phe Glu Glu Ile Pro Glu
85           90           95
Glu Tyr Leu

```

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 98 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

```

Ile Met Glu Ala Gly Glu Glu Cys Asp Cys Gly Ser Pro Glu Asn Pro
1           5           10           15
Cys Asp Asp Ala Ala Thr Cys Lys Leu Arg Pro Gly Ala Gln Cys Ala
20           25           30
Glu Gly Leu Cys Cys Asp Gln Cys Lys Phe Leu Lys Glu Gly Thr Val
35           40           45
Cys Arg Arg Ala Arg Gly Asp Asp Val Asn Asp Tyr Cys Asn Gly Ile
50           55           60
Ser Ala Gly Cys Pro Arg Asn Pro Phe His Gly Gly Gly Gly Gly Pro

```

(2) INFORMATION FOR SEQ ID NO:10:

(A) LENGTH: 288 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(111) HYPOTHETICAL: N

(iv) ANTI-SENSE: N

GGTCCGCGTC	CGGGTGGTGG	TGGTAACGGT	GACTTCGAAG	AAATCCCGGA	AGAATACCTG	60
GGTGGTGGTG	GTGAAGCTGG	TGAAGAATGC	GACTGCCGAT	CCCCGGAAAA	CCCGTGCGAC	120
GACGCTGCTA	CCTGCAAAC	GCGTCCGGGT	GCTCAGTGCG	CTGAAGGTCT	GTGCTGCGAC	180
CAGTGCAAAT	TCNNNAAAGA	AGGTACCGTT	TGCCGTCGTG	CTCGTGGTGA	CGACGTTAAC	240
GACTACTGCA	ACGGTATCTC	TGCAGGTTGC	CCGCGTAACC	CGTTCCAC		288

(A) LENGTH: 288 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(111) HYPOTHETICAL: N

(iv) **ANTI-SENSE: N**

(x1) SEQUENCE DESCRIPTION: SEQ ID NO:11:

GAAGCTGGTG AAGAATGCGA CTGCGGATCC CCGGAAAACC CGTGCGACGA CGCTGCTACC 60
TGCAAAGTGC GTCCGGGTGC TCAGTCCGCT GAAGGTCTGT GCTGCGACCA GTGCAAATTC 120
NNNAAAGAAG GTACCGTTTG CCGTCGTGCT CCGTGGTGACG ACGTTAACGA CTACTGCAAC 180
GGTATCTCTG CAGGTTGCCC GCGTAACCGG TTCCACGGTG GTGGTGGTGG TCCGGGTCGG 240
GGTGGTGGTG GTAACGGTGA CTTCAAGAA ATCCCGGAAG AATACCTG 288

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 31 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: N

(iv) ANTI-SENSE: N

(x1) SEQUENCE DESCRIPTION: SEQ ID NO:12:

AATTCGGAAG CTGGTGAAGA ATGCGACTGC G 31

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 31 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: N

(iv) ANTI-SENSE: N

(x1) SEQUENCE DESCRIPTION: SEQ ID NO:13:

GATCCGCAGT CGCATTCTTC ACCAGCTTCC G

31

(2) INFORMATION FOR SEQ ID NO:14:

(1) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 41 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: N

(iv) ANTI-SENSE: N

(x1) SEQUENCE DESCRIPTION: SEQ ID NO:14:

AATTCGGGTC CGCGTCCGGG TGGTGGTGGT AACGGTGACT T

41

(2) INFORMATION FOR SEQ ID NO:15:

(1) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 39 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: N

(iv) ANTI-SENSE: N

(x1) SEQUENCE DESCRIPTION: SEQ ID NO:15:

CGAAGTCACC GTTACCACCA CCACCCGGAC GCGGACCCG

39

(2) INFORMATION FOR SEQ ID NO:16:

(1) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 51 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: N

(iv) ANTI-SENSE: N

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

ACGTCGGTAC CAGGCGCGCG TATCGAGGGT AGGATCATGG AAGCTGGTGA A

51

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 36 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: N

(iv) ANTI-SENSE: N

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

GCAAACGGTA CCTTCTTTCA GGAATTGCA CTGGTC

36

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

Phe Pro Arg Pro Gly Gly Gly Asn Gly Asp Phe Glu Glu Ile Pro
1 5 10 15

Glu Glu Tyr Leu
20

- 73 -

CLAIMS

We claim:

1. A bifunctional inhibitor of both platelet activation and thrombin comprising:
 - a) a glycoprotein IIb/IIIa inhibitory moiety; and
 - b) a thrombin inhibitory moiety, wherein said thrombin inhibitory moiety consists of:
 - i) a catalytic site-directed moiety that binds to and inhibits the active site of thrombin; bound to
 - ii) a linker moiety characterized by a backbone chain having a calculated length of between about 18Å and about 42Å; bound to
 - iii) an anion binding exosite associating moiety.

2. The bifunctional inhibitor according to claim 1, wherein said glycoprotein IIb/IIIa inhibitory domain consists of the formula:

$X_1\text{-Cys-R}_1\text{-R}_2\text{-R}_2\text{-R}_3\text{-Gly-Asp-R}_4\text{-R}_2\text{-R}_2\text{-R}_2\text{-R}_2\text{-Cys-Y}_1$,
 wherein X_1 is hydrogen or at least one amino acid; Y_1 is OH or at least one amino acid; R_1 , each R_2 , either the same or different, and R_3 is any amino acid; and R_4 is a bond or any amino acid;


said catalytic site-directed moiety consists of the formula:

$X_2\text{-A}_1\text{-Pro-A}_2$,

wherein X_2 is hydrogen or from 1 to 12 residues, either the same or different, of any amino acid; A_1 is Arg or Lys; and A_2 is a bond or from 1 to 3 residues, either the same or different, of any amino acid;
 said linker consists of from 6 to 14 residues, either the same or different, of any amino acid; and

- 74 -

said anion binding exosite associating moiety consists of the formula:



wherein each B_1 , either the same or different, is any anionic amino acid; B_2 is any amino acid; B_3 is Ile, Val, Leu or Phe; B_4 is Tyr, Trp, Phe, Leu, Ile, Val, Pro or a dipeptide consisting of one of these amino acids and any amino acid; and Y_2 is OH or from 1 to 5 residues, either the same or different, of any amino acid.

3. The bifunctional inhibitor according to claim 2, wherein R_1 is any cationic amino acid, R_3 is Arg, R_4 is Trp, Phe, Asp or a bond, each B_1 is Glu, B_2 is Glu, B_3 is Ile, B_4 is a dipeptide Tyr-Leu or Tyr(OSO₃H)-Leu.

4. The bifunctional inhibitor according to claim 3 comprising the amino acid sequence (SEQ ID NO:2):

Gly Pro Arg Pro Gly Gly Gly Gly Asn Gly Asp Phe Glu Glu
Ile Pro Glu Glu Tyr Leu Gly Gly Gly Gly Glu Ala Gly Glu
Glu Cys Asp Cys Gly Ser Pro Glu Asn Pro Cys Asp Asp Ala
Ala Thr Cys Lys Leu Arg Pro Gly Ala Gln Cys Ala Glu Gly
Leu Cys Cys Asp Gln Cys Lys Phe Xaa Lys Glu Gly Thr Val
Cys Arg Arg Ala Arg Gly Asp Asp Val Asn Asp Tyr Cys Asn
Gly Ile Ser Ala Gly Cys Pro Arg Asn Pro Phe His,
wherein Xaa is any amino acid.

5. The bifunctional inhibitor according to claim 4 selected from the group consisting of N-appilog (amino acids 11-106 of SEQ ID NO:4), Met-N-appilog (amino acids 10-106 of SEQ ID NO:4), Ala-Asn-Ser-N-appilog (SEQ ID NO:5), Gly-Ser-Ile-Glu-Gly-Arg-Pro-Glu-

- 75 -

Phe-Met-N-appilog (SEQ ID NO:4), N-appilog(Leu₆₅) (amino acids 2-98 of SEQ ID NO:6) and Ile-Met-N-appilog(Leu₆₅) (SEQ ID NO:6).

6. The bifunctional inhibitor according to claim 3 comprising the amino acid sequence (SEQ ID NO:3):

Glu Ala Gly Glu Glu Cys Asp Cys Gly Ser Pro Glu Asn Pro
Cys Asp Asp Ala Ala Thr Cys Lys Leu Arg Pro Gly Ala Gln
Cys Ala Glu Gly Leu Cys Cys Asp Gln Cys Lys Phe Xaa Lys
Glu Gly Thr Val Cys Arg Arg Ala Arg Gly Asp Asp Val Asn
Asp Tyr Cys Asn Gly Ile Ser Ala Gly Cys Pro Arg Asn Pro
Phe His Gly Gly Gly Gly Gly Pro Arg Pro Gly Gly Gly Gly
Asn Gly Asp Phe Glu Glu Ile Pro Glu Glu Tyr Leu,
wherein Xaa is any amino acid.

7. The bifunctional inhibitor according to claim 6 selected from the group consisting of C-appilog (amino acid 11-106 of SEQ ID NO:7), Met-C-appilog (amino acid 10-106 of SEQ ID NO:7), Ala-Asn-Ser-C-appilog (SEQ ID NO:8), Gly-Ser-Ile-Glu-Gly-Arg-Pro-Glu-Phe-Met-C-appilog (SEQ ID NO:7), C-appilog(Leu₄₁) (amino acids 2-98 of SEQ ID NO:9) and Ile-Met-C-appilog(Leu₄₁) (SEQ ID NO:9).

8. A DNA sequence coding on expression for the bifunctional inhibitor according to claim 4, said DNA sequence being selected from the group consisting of:

a) DNA sequences comprising the nucleic acid sequence (SEQ ID NO:10): GGT CCG CGT CCG
GGT GGT GGT GGT AAC GGT GAC TTC GAA GAA ATC CCG GAA GAA
TAC CTG GGT GGT GGT GGT GAA GCT GGT GAA GAA TGC GAC TGC
GGA TCC CCG GAA AAC CCG TGC GAC GAC GCT GCT ACC TGC AAA
CTG CGT CCG GGT GCT CAG TGC GCT GAA GGT CTG TGC TGC GAC

- 76 -

CAG TGC AAA TTC NNN AAA GAA GGT ACC GTT TGC CGT CGT GCT
CGT GGT GAC GAC GTT AAC GAC TAC TGC AAC GGT ATC TCT GCA
GGT TGC CCG CGT AAC CCG TTC CAC, wherein each N, either
the same or different is any nucleotide; and

b) DNA sequences which as a result of
the degeneracy of the genetic code code on expression
for the bifunctional inhibitor coded for on expression
by the nucleic acid sequence of a).

9. A DNA sequence coding on expression for
the bifunctional inhibitor according to claim 6, said
DNA sequence being selected from the group consisting
of:

a) DNA sequences comprising the
nucleic acid sequence (SEQ ID NO:11): GAA GCT GGT GAA
GAA TGC GAC TGC GGA TCC CCG GAA AAC CCG TGC GAC GAC GCT
GCT ACC TGC AAA CTG CGT CCG GGT GCT CAG TGC GCT GAA GGT
CTG TGC TGC GAC CAG TGC AAA TTC NNN AAA GAA GGT ACC GTT
TGC CGT CGT GCT CGT GGT GAC GAC GTT AAC GAC TAC TGC AAC
GGT ATC TCT GCA GGT TGC CCG CGT AAC CCG TTC CAC GGT GGT
GGT GGT GGT CCG CGT CCG GGT GGT GGT AAC GGT GAC TTC
GAA GAA ATC CCG GAA GAA TAC CTG, wherein each N, either
the same or different, is any nucleotide; and

b) DNA sequences which as a result of
the degeneracy of the genetic code code on expression
for the bifunctional inhibitor coded for on expression
by the nucleic acid sequence of a).


10. A recombinant DNA molecule comprising a
first DNA sequence according to claim 8 or 9.

11. The recombinant DNA molecule according
to claim 10, further comprising a second DNA sequence
coding for an OmpA signal sequence, said second DNA

- 77 -

sequence being operatively linked to said first DNA sequence.

12. The recombinant DNA molecule according to claim 10, further comprising a malE DNA sequence, said malE DNA sequence being linked to said first DNA sequence so as to code on expression for a fusion protein having the formula:



wherein Z_1 is hydrogen or the amino acid sequence of the maltose binding protein signal sequence, Z_2 is the amino acid sequence of the maltose binding protein, Z_3 is a bond or from 1 to 20 residues, either the same or different, of any amino acid, and Z_4 is the amino acid sequence of the bifunctional inhibitor according to claim 4 or 5.

13. A host transformed with a recombinant DNA molecule according to any of claims 10 to 12, wherein said host is selected from the group consisting of bacterial cells, animal cells, yeast and other fungal cells and plant cells.

14. The host according to claim 13, wherein said host is E. coli.


15. A process for producing a bifunctional inhibitor according to claim 4 or 6, said process comprising the steps of:

- a) culturing a host according to claim 13; and
- b) recovering said bifunctional inhibitor from said culture.

- 78 -

16. A process for producing a bifunctional inhibitor according to claim 4 or 6, comprising the steps of:

a) culturing an E. coli host cell harboring a recombinant DNA molecule according to claim 12, wherein said recombinant DNA molecule comprises a DNA sequence which codes on expression for a fusion protein having the formula:



wherein Z_1 is hydrogen;

b) isolating said host cell from said culture;

c) extracting a soluble cytoplasmic fraction from said host cell;

d) contacting said cytoplasmic fraction with an amylose chromatography resin under a first buffer condition which allows a maltose binding protein-containing molecule to bind to said resin;

e) transferring said amylose chromatography resin to a second buffer condition which allows said maltose binding protein-containing molecule to elute from said resin;

f) digesting said eluted maltose binding protein-containing molecule with Factor Xa to separate a maltose binding protein portion of said fusion protein from a bifunctional inhibitor portion of said fusion protein; and

g) recovering the bifunctional inhibitor portion from said digest.

17. A process for producing a bifunctional inhibitor according to claim 4 or 6, comprising the steps of:

a) culturing an E. coli host cell harboring a recombinant DNA molecule according to

- 79 -

claim 12, wherein said recombinant DNA molecule comprises a DNA sequence which codes on expression for a fusion protein having the formula:

$$Z_1-Z_2-Z_3-Z_4,$$


wherein Z_1 is the maltose binding protein signal sequence;

- b) isolating said host cell from said culture;
- c) extracting a soluble periplasmic fraction from said host cell;
- d) contacting said periplasmic fraction with an amylose chromatography resin under a first buffer condition which allows a maltose binding protein-containing molecule to bind to said resin;
- e) transferring said amylose chromatography resin to a second buffer condition which allows said maltose binding protein-containing molecule to elute from said resin;
- f) digesting said eluted maltose binding protein-containing molecule with Factor Xa to separate a maltose binding protein portion of said fusion protein from a bifunctional inhibitor portion of said fusion protein; and
- g) recovering the bifunctional inhibitor portion from said digest.

18. A process for producing a bifunctional inhibitor according to claim 4 or 6, wherein Xaa is any amino acid except methionine, said process comprising the steps of:

- a) culturing an *E. coli* host cell harboring a recombinant DNA molecule according to claim 12, wherein said recombinant DNA molecule comprises a DNA sequence which codes on expression for a fusion protein having the formula:

- 80 -



wherein Z_1 is hydrogen;

b) isolating said host cell from said culture;

c) extracting a soluble cytoplasmic fraction from said host cell;

d) contacting said cytoplasmic fraction with an amylose chromatography resin under a first buffer condition which allows a maltose binding protein-containing molecule to bind to said resin;


e) transferring said amylose chromatography resin to a second buffer condition which allows said maltose binding protein-containing molecule to elute from said resin;

f) treating said eluted maltose binding protein-containing molecule with cyanogen bromide to separate a maltose binding protein portion of said fusion protein from a bifunctional inhibitor portion of said fusion protein; and

g) recovering the bifunctional inhibitor portion from said digest.

19. A process for producing a bifunctional inhibitor according to claim 4 or 6, wherein Xaa is any amino acid except methionine, said process comprising the steps of:

a) culturing an E. coli host cell harboring a recombinant DNA molecule according to claim 12, wherein said recombinant DNA molecule comprises a DNA sequence which codes on expression for a fusion protein having the formula:



wherein Z_1 is the maltose binding protein signal sequence;

- 81 -

- b) isolating said host cell from said culture;
- c) extracting a soluble periplasmic fraction from said host cell;
- d) contacting said periplasmic fraction with an amylose chromatography resin under a first buffer condition which allows a maltose binding protein-containing molecule to bind to said resin;
- e) transferring said amylose chromatography resin to a second buffer condition which allows said maltose binding protein-containing molecule to elute from said resin;
- f) treating said eluted maltose binding protein-containing molecule with cyanogen bromide to separate a maltose binding protein portion of said fusion protein from a bifunctional inhibitor portion of said fusion protein; and
- g) recovering the bifunctional inhibitor portion from said digest.

20. A pharmaceutically acceptable composition for inhibiting both thrombin and platelet-mediated function in a patient or in extracorporeal blood, said composition comprising a pharmaceutically effective amount of a bifunctional inhibitor according to any one of claims 1 to 7 and a pharmaceutically acceptable carrier.

21. The pharmaceutically acceptable composition according to claim 20, further comprising a pharmaceutically effective amount of a thrombolytic molecule selected from the group consisting of tissue plasminogen activator purified from natural sources, recombinant tissue plasminogen activator, streptokinase, urokinase, prourokinase, anisolated

- 82 -

streptokinase plasminogen activator complex (ASPAC), animal salivary gland plasminogen activators and biologically active derivatives of any of the above.

22. The pharmaceutically acceptable composition according to claim 20, wherein said pharmaceutically effective amount is between about 1 μ g/kg body weight/day to about 5 mg/kg body weight/day.

23. The pharmaceutically acceptable composition according to claim 21, wherein said pharmaceutically effective amount of said thrombolytic molecule is between about 10% and 80% of the conventional dosage range.

24. A method for treating or preventing thrombotic disease in a patient comprising the step of administering to said patient a pharmaceutically acceptable composition according to any one of claims 20 to 23.

25. A method for simultaneously inhibiting thrombin- and platelet-mediated functions in a patient comprising the step of administering to said patient a pharmaceutically acceptable composition according to claim 20 or 22.

26. A method for increasing reocclusion time in a patient comprising the step of administering to said patient a pharmaceutically acceptable composition according to any one of claims 20 to 23.

27. A method for decreasing reperfusion time in a patient comprising the step of administering to

- 83 -

said patient a pharmaceutically acceptable composition according to any one of claims 20 to 23.

28. A method for treating metastatic cell growth in a patient comprising the step of administering to said patient a pharmaceutically acceptable composition according to claim 20 or 22.

1/15




FIG. 1

B	A	BH	H
S	SB	AsgX	iH
p	pa	vpH	np
E	7n	alAo	ca
1	11	1211	21
/			
AATTCATGAAAGAAGGTACCGTTTGCCGTCGTCTCGAGGTGACGACGTTAACGACTACT			
121			180
TTAAGTACTTTCTTCCATGGCAACGACGACGAGCTCCACTGCTGCAATTGCTGATGA			
PheMetLysGluGlyThrValCysArgArgAlaArgGlyAspAspValAsnAspTyrCys			
B	P	H	
S		i	
p	S	n	
M	t	d	
1	1	3	
GCAACGGTATCTCTGCAGGTTGCCCGGTAACCGTTCCTACTGATGA			
181			232
CGTTGCCATAGACAGCTCCAACGGGCGCATTTGGGCAAGGTGACTACTTCGA			
AsnGlyIleSerAlaGlyCysProArgAsnProPheHisEndEndSer???			

FIG. 1 (cont'd)

3/15

```
1      CATGGAAGCTGGTGAAGAATGCG
2      CTTGACCACTTCTTACGCTGACGCCTAGGG
3      GATCCCCGGAAAACCCGTGCTGCGACGC
4      GCCTTTTGGGCACGACGCTGCGCCGGTG
5      GGCCACCTGCAAACCTTCGTCCGGGTGCACAGTGT
6      GACGTTTGAAGCAGGCCACGT
7      GCAGAAGGTCTGTGCTGCGACCAAGTGCAAAT
8      GTCACACGTCTTCCAGACACGACGCTGGTCACGTTTAAGTACT
9      TCATGAAAGAAGGTACCGTTTGCCGTCGTGC
10     TTCTTCCATGGCAAACGGCAGCACGAGCTCC
11     TCGAGGTGACGACGTTAACGACTACTGCAACGG
12     ACTGCTGCAATTGCTGATGACGAAGCCATAGAG
13     TATCTCTGCAGGTTGCCCGCGTAACCCGTTCCACTGATGA
14     ACGTCCAACGGGCGCATTGGGCAAGGTGACTACTTCGA
```

FIG. 2

SUBSTITUTE SHEET




FIG. 4

6 / 15

```
1 CATGGGTCCGCGTCCGGGTGGTGGTGGTAACGGTGAC
2 CCAGGCGCAGGCCACCACCACCATTGCCACTGAAGC
3 TTCGAAGAAATCCCGGAAGAATACCTGG
4 TTCTTTAGGGCCTTCTTATGGACCCACC
5 GTGGTGGTGGTGAAGCTGGTGAAGAATGCG
6 ACCACCACTTCGACCACTTCTTAC
```

FIG. 5

```
1 GGTGCCCCGCGTAACCCGTTCCACGGTG
2 ACGTCCAACGGGCGCATTGGGCAAGGTG
3 GTGGTGGTGGTCCGCGTCCGGGTGGTGGTGGTAACGGTGAC
4 CCACCACCACCAGGCGCAGGCCACCACCACCATTGCCACTGAAGC
5 TTCGAAGAAATCCCGGAAGAATACCTGTGATGA
6 TTCTTTAGGGCCTTCTTATGGACACTACTTCGA
```

FIG. 6

SUBSTITUTE SHEET

7/15




FIG. 7

SUBSTITUTE SHEET

8/15




FIG. 8

SUBSTITUTE SHEET

9 / 15




FIG. 8 (cont'd)

SUBSTITUTE SHEET

10 / 15




FIG. 9

SUBSTITUTE SHEET


11 / 15

male ... TCG AGC TCG GTA CCC GGC CGG GGA TCC ATC GAG GGT AGG CCT GAA TTC ATG appilog
Ser Ser Ser Val Pro Gly Arg Gly Ser Ile Glu Gly Arg Pro Glu Phe Met

FACTOR Xa
CLEAVAGE SITE

FIG. 10

SUBSTITUTE SHEET



13 / 15




FIG. 12

SUBSTITUTE SHEET

14 / 15




FIG. 13

SUBSTITUTE SHEET

15 / 15




FIG. 14

SUBSTITUTE SHEET

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 91/09108

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC		
Int.C1.5	C 12 N 15/62	C 12 N 15/12
C 12 N 15/31	C 07 K 13/00	C 12 P 21/02
/(C12N1/21 C12R1:19) (A61K37/64.37/54)		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
Int.C1.5	C 12 N	C 07 K A 61 K
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
Y	Biochemistry, volume 29, no. 30, 31 July 190 (Washington DC, US) J.M. Maraganore et al.: "Design and characterization of hirulogs: A novel class of bivalent peptide inhibitors of thrombin", pages 7095-7101, see abstract ---	2
X	WO,A,9008772 (BIOGEN INC.) 9 August 1990 (cited in the application)	1
Y	---	2
X	Journal of Biological Chemistry, volume 266, no. 18, 25 June 1991 (Baltimore, US) F.C. Church et al.: "Chimeric antithrombin peptide", pages 11975-11979, see abstract --- -/-	1
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>¹⁰ Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"I" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p> </div> </div>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
02-03-1992	27. 03. 92	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE	Nicole De Bie	

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claims No.
A	EP, A, 0382451 (MERCK & CO. INC./TEMPLE UNIVERSITY) 16 August 1990, see abstract; page 12, lines 30-42	21

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. ☒ OBSERVATION WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE ¹

This International search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim numbers _____ because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 24-28 are directed to a method of treatment of the human body (Article 52(4) EPC) the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claim numbers _____ because they relate to parts of the International application that do not comply with the prescribed requirements to such an extent that no meaningful International search can be carried out, specifically:
3. ☐ Claim numbers _____ because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING ²

This International Searching Authority found multiple inventions in this International application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International search report covers all searchable claims of the International application.
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this International search report covers only those claims of the International application for which fees were paid, specifically claims: _____
3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers: _____
4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

US 9109108

SA 55200

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 12/03/92. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A- 9008772	09-08-90	EP-A- 0455722	13-11-91
EP-A- 0382451	16-08-90	CA-A- 2009390	07-08-90
		JP-A- 3197495	28-08-91